OA19258A - Triazolopyrazine - Google Patents
Triazolopyrazine Download PDFInfo
- Publication number
- OA19258A OA19258A OA1201500152 OA19258A OA 19258 A OA19258 A OA 19258A OA 1201500152 OA1201500152 OA 1201500152 OA 19258 A OA19258 A OA 19258A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- substituted
- groups
- iii
- anyone
- Prior art date
Links
- DFDJVPRVKHSWQH-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyrazine Chemical compound C1=NC=CN2N=CN=C21 DFDJVPRVKHSWQH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 109
- -1 2-pyridyl Chemical group 0.000 claims description 162
- 239000011780 sodium chloride Substances 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 29
- 125000001072 heteroaryl group Chemical group 0.000 claims description 27
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 239000000969 carrier Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 210000004556 Brain Anatomy 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 230000001085 cytostatic Effects 0.000 claims description 4
- 239000000824 cytostatic agent Substances 0.000 claims description 4
- 230000001472 cytotoxic Effects 0.000 claims description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 210000000481 Breast Anatomy 0.000 claims description 3
- 210000001072 Colon Anatomy 0.000 claims description 3
- 210000004185 Liver Anatomy 0.000 claims description 3
- 210000004072 Lung Anatomy 0.000 claims description 3
- 210000001672 Ovary Anatomy 0.000 claims description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 3
- 210000001685 Thyroid Gland Anatomy 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 230000003394 haemopoietic Effects 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical group C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 claims description 2
- 125000005418 aryl aryl group Chemical group 0.000 claims description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 6
- 230000002159 abnormal effect Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
- 125000004432 carbon atoms Chemical group C* 0.000 description 41
- 239000000543 intermediate Substances 0.000 description 35
- 239000000203 mixture Substances 0.000 description 32
- 239000011541 reaction mixture Substances 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 28
- 230000000875 corresponding Effects 0.000 description 26
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 26
- 125000003118 aryl group Chemical group 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 18
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- 239000002253 acid Substances 0.000 description 14
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- 125000000623 heterocyclic group Chemical group 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 13
- 201000009030 carcinoma Diseases 0.000 description 13
- 125000000392 cycloalkenyl group Chemical group 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 102100015500 BRD4 Human genes 0.000 description 12
- 101700009767 BRD4 Proteins 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cells Anatomy 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 125000002947 alkylene group Chemical group 0.000 description 10
- 150000002430 hydrocarbons Chemical group 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 125000004429 atoms Chemical group 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 102000001805 Bromodomains Human genes 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000004450 alkenylene group Chemical group 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 125000005842 heteroatoms Chemical group 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 108050009021 Bromodomains Proteins 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 125000004419 alkynylene group Chemical group 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 125000000262 haloalkenyl group Chemical group 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 208000003362 Bronchogenic Carcinoma Diseases 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 4
- FABUFPQFXZVHFB-PVYNADRNSA-N Ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 4
- 208000007538 Neurilemmoma Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 125000000732 arylene group Chemical group 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 125000005724 cycloalkenylene group Chemical group 0.000 description 4
- 125000002993 cycloalkylene group Chemical group 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 125000005549 heteroarylene group Chemical group 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000011343 solid material Substances 0.000 description 4
- NWTHBRAKRNFBIW-UHFFFAOYSA-N (5-benzyl-1-methylpyrazol-4-yl)boronic acid Chemical compound CN1N=CC(B(O)O)=C1CC1=CC=CC=C1 NWTHBRAKRNFBIW-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- 229960001561 Bleomycin Drugs 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 3
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- 201000004253 NUT midline carcinoma Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 206010039667 Schwannoma Diseases 0.000 description 3
- 238000003016 alphascreen Methods 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229960002014 ixabepilone Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 150000002829 nitrogen Chemical group 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium triacetoxyborohydride Substances [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HUDDVAQVBCSULS-UHFFFAOYSA-N (1-methyl-5-phenoxypyrazol-4-yl)boronic acid Chemical compound CN1N=CC(B(O)O)=C1OC1=CC=CC=C1 HUDDVAQVBCSULS-UHFFFAOYSA-N 0.000 description 2
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 2
- ISOFRRQGTLHGQB-UHFFFAOYSA-N (4-bromo-2-methylpyrazol-3-yl)-phenylmethanol Chemical compound CN1N=CC(Br)=C1C(O)C1=CC=CC=C1 ISOFRRQGTLHGQB-UHFFFAOYSA-N 0.000 description 2
- VQHRZZISQVWPLK-LLKZIRPDSA-N (7S,9S)-7-[(2R,4S,5R,6S)-5-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)C[C@H](O[C@@H]2C3=C(O)C=4C(=O)C5=CC=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)O[C@H]1C VQHRZZISQVWPLK-LLKZIRPDSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
- RZVJQUMDJUUBBF-UHFFFAOYSA-N 2,4-dichloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CN=C(Cl)C=C1Cl RZVJQUMDJUUBBF-UHFFFAOYSA-N 0.000 description 2
- NFIXBCVWIPOYCD-UHFFFAOYSA-N 2-(4-benzylphenoxy)-N,N-diethylethanamine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 NFIXBCVWIPOYCD-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 2
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical class OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- YQRKWRYXMMDZBW-UHFFFAOYSA-N 4-iodo-1-methyl-5-phenoxypyrazole Chemical compound CN1N=CC(I)=C1OC1=CC=CC=C1 YQRKWRYXMMDZBW-UHFFFAOYSA-N 0.000 description 2
- HSILBGLXKSWKOO-UHFFFAOYSA-N 5-benzyl-4-bromo-1-methylpyrazole Chemical compound CN1N=CC(Br)=C1CC1=CC=CC=C1 HSILBGLXKSWKOO-UHFFFAOYSA-N 0.000 description 2
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 229950004810 ATAMESTANE Drugs 0.000 description 2
- 208000009956 Adenocarcinoma Diseases 0.000 description 2
- RMRFFCXPLWYOOY-UHFFFAOYSA-N Allyl radical Chemical group [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- UPALIKSFLSVKIS-UHFFFAOYSA-N Amonafide Chemical compound NC1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 UPALIKSFLSVKIS-UHFFFAOYSA-N 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- PEPMWUSGRKINHX-TXTPUJOMSA-N Atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 2
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000009755 Bone Cysts Diseases 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N Bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- 229960004117 Capecitabine Drugs 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 229960000684 Cytarabine Drugs 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- QXRSDHAAWVKZLJ-TYFQHMATSA-N Epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@@]2(C)CCC[C@@H]([C@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-TYFQHMATSA-N 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N Exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 2
- 206010017758 Gastric cancer Diseases 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- HYFHYPWGAURHIV-JFIAXGOJSA-N Homoharringtonine Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229950010895 Midostaurin Drugs 0.000 description 2
- 229960004857 Mitomycin Drugs 0.000 description 2
- 210000000214 Mouth Anatomy 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- DVTQQYPBIOJPAN-UHFFFAOYSA-N N'-(3-chloropyrazin-2-yl)-2,2,2-trifluoroacetohydrazide Chemical compound FC(F)(F)C(=O)NNC1=NC=CN=C1Cl DVTQQYPBIOJPAN-UHFFFAOYSA-N 0.000 description 2
- RDSACQWTXKSHJT-NSHDSACASA-N N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 2
- 102100003676 NUTM1 Human genes 0.000 description 2
- 101700054832 NUTM1 Proteins 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- BWKDAMBGCPRVPI-ZQRPHVBESA-N Ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 2
- 206010025310 Other lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 102100008873 POMC Human genes 0.000 description 2
- 108060006375 POMC Proteins 0.000 description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 2
- 229960001373 Pegfilgrastim Drugs 0.000 description 2
- 229960002340 Pentostatin Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 210000003800 Pharynx Anatomy 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 229960003171 Plicamycin Drugs 0.000 description 2
- 108010001645 Rituximab Proteins 0.000 description 2
- 208000000649 Small Cell Carcinoma Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M Sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- 229950007967 Tesmilifene Drugs 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N Vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- 229960004528 Vincristine Drugs 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- VKYABZXPNHHDSD-UHFFFAOYSA-N bis(2-methylpropyl)alumanylium;hydride Chemical compound [H-].CC(C)C[Al+]CC(C)C VKYABZXPNHHDSD-UHFFFAOYSA-N 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000005569 butenylene group Chemical group 0.000 description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
- 125000005622 butynylene group Chemical group 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001973 epigenetic Effects 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 2
- 229950009429 exatecan Drugs 0.000 description 2
- 229960000255 exemestane Drugs 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 239000008079 hexane Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000005945 imidazopyridyl group Chemical group 0.000 description 2
- 230000001965 increased Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000003211 malignant Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 2
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000004430 oxygen atoms Chemical group O* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrugs Drugs 0.000 description 2
- DITHIFQMPPCBCU-UHFFFAOYSA-N propa-1,2-diene Chemical group [CH]=C=C DITHIFQMPPCBCU-UHFFFAOYSA-N 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 229960004432 raltitrexed Drugs 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 201000010208 seminoma Diseases 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 2
- 201000007423 tubular adenocarcinoma Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960003862 vemurafenib Drugs 0.000 description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- NDTYTMIUWGWIMO-SNVBAGLBSA-N (-)-isocarveol Chemical compound CC(=C)[C@H]1CCC(CO)=CC1 NDTYTMIUWGWIMO-SNVBAGLBSA-N 0.000 description 1
- 229930007631 (-)-perillyl alcohol Natural products 0.000 description 1
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- AKJHMTWEGVYYSE-FXILSDISSA-N (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide Chemical compound C=1C=C(O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-FXILSDISSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FIITXXIVUIXYMI-RQJHMYQMSA-N (2R,3S)-3-[(2-nitroimidazol-1-yl)methoxy]butane-1,2,4-triol Chemical compound OC[C@@H](O)[C@H](CO)OCN1C=CN=C1[N+]([O-])=O FIITXXIVUIXYMI-RQJHMYQMSA-N 0.000 description 1
- IEJSCSAMMLUINT-NRFANRHFSA-N (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid Chemical compound C([C@H](NC(=O)C1=CC=C(C=C1F)N(CC#C)CC=1C=C2C(=O)N=C(NC2=CC=1C)C)C(O)=O)CC=1N=NNN=1 IEJSCSAMMLUINT-NRFANRHFSA-N 0.000 description 1
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2S)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1R,2R)-1,2-dimethanidylcyclohexane;5-fluoro-1H-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2S)-2-[[4-[2-[(6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- OJLHWPALWODJPQ-QNWVGRARSA-N (2S)-2-amino-5-[[(2R)-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]-1-[[(R)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 OJLHWPALWODJPQ-QNWVGRARSA-N 0.000 description 1
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2S)-N-benzyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 description 1
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 description 1
- PUUGNIKJWZNTBK-UHFFFAOYSA-N (3-chloropyrazin-2-yl)hydrazine Chemical compound NNC1=NC=CN=C1Cl PUUGNIKJWZNTBK-UHFFFAOYSA-N 0.000 description 1
- LSXOBYNBRKOTIQ-RQUBOUMQSA-N (3S,10R,13E,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NCC(C)(C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 LSXOBYNBRKOTIQ-RQUBOUMQSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- CLLFEJLEDNXZNR-UUOKFMHZSA-N (4aR,6R,7R,7aS)-6-(6-amino-8-chloropurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Cl CLLFEJLEDNXZNR-UUOKFMHZSA-N 0.000 description 1
- NBRQRXRBIHVLGI-OWXODZSWSA-N (4aS,5aR,12aR)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)N)C(=O)C1 NBRQRXRBIHVLGI-OWXODZSWSA-N 0.000 description 1
- LDSVTELDHUQWGO-UHFFFAOYSA-N (5-bromo-3-chloropyrazin-2-yl)hydrazine Chemical compound NNC1=NC=C(Br)N=C1Cl LDSVTELDHUQWGO-UHFFFAOYSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-L (E)-4-hydroxy-2-oxido-4-oxobut-2-enoate Chemical compound OC(=O)\C=C(\[O-])C([O-])=O UWYVPFMHMJIBHE-OWOJBTEDSA-L 0.000 description 1
- NPUZFKMKEFBWLV-SNAWJCMRSA-N (E)-pent-2-ene Chemical group [CH2]C\C=C\C NPUZFKMKEFBWLV-SNAWJCMRSA-N 0.000 description 1
- WILKISNQLXFBSQ-UHFFFAOYSA-N (E)-pent-2-ene Chemical group [CH2]C=CCC WILKISNQLXFBSQ-UHFFFAOYSA-N 0.000 description 1
- MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 description 1
- NNYBQONXHNTVIJ-QGZVFWFLSA-N (R)-etodolac Chemical compound C1CO[C@](CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-QGZVFWFLSA-N 0.000 description 1
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 description 1
- SHXCUQHMQIBOAR-UHFFFAOYSA-N 1,2,3$l^{2}-dioxaborolane Chemical compound [B]1CCOO1 SHXCUQHMQIBOAR-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1,2,3-triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- 125000004815 1,2-dimethylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([*:2])C([H])([H])[H] 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- VDMKJSJJXQDICL-ZXVJYWQYSA-N 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O.COC1=C(OC)C(OC)=CC(C(=O)C(=O)N2[C@@H](CCCC2)C(=O)OC(CCCC=2C=NC=CC=2)CCCC=2C=NC=CC=2)=C1 VDMKJSJJXQDICL-ZXVJYWQYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-M 1-carboxynaphthalen-2-olate Chemical compound C1=CC=CC2=C(C([O-])=O)C(O)=CC=C21 UPHOPMSGKZNELG-UHFFFAOYSA-M 0.000 description 1
- YQHWURFNAULYNW-UHFFFAOYSA-N 1-hydroxyimino-1-phenylpropan-2-one Chemical compound CC(=O)C(=NO)C1=CC=CC=C1 YQHWURFNAULYNW-UHFFFAOYSA-N 0.000 description 1
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 1
- BADMGRJDJPQBLS-UNTFVMJOSA-N 1-methyl-1-nitroso-3-[(2R,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]urea Chemical compound O=NN(C)C(=O)N[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O BADMGRJDJPQBLS-UNTFVMJOSA-N 0.000 description 1
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 description 1
- 125000004806 1-methylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N 17-Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- 125000004825 2,2-dimethylpropylene group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[*:1])C([H])([H])[*:2] 0.000 description 1
- XYVIKUTYMMOQFT-UHFFFAOYSA-L 2,2-ditert-butylpropanedioate Chemical compound CC(C)(C)C(C([O-])=O)(C([O-])=O)C(C)(C)C XYVIKUTYMMOQFT-UHFFFAOYSA-L 0.000 description 1
- CVKGBEGKZIIWRA-UHFFFAOYSA-N 2,3,4,5,6,7-hexahydro-1H-indene Chemical group C1CCCC2=C1CCC2 CVKGBEGKZIIWRA-UHFFFAOYSA-N 0.000 description 1
- PTLWKRLAWHBMLM-UHFFFAOYSA-N 2,3-dihydroazete Chemical compound C1CN=C1 PTLWKRLAWHBMLM-UHFFFAOYSA-N 0.000 description 1
- YRULUXDRMGWMDA-UHFFFAOYSA-K 2-(2-ethylhexanoyloxy)ethanethiolate;methyltin(3+) Chemical compound CCCCC(CC)C(=O)OCCS[Sn](C)(SCCOC(=O)C(CC)CCCC)SCCOC(=O)C(CC)CCCC YRULUXDRMGWMDA-UHFFFAOYSA-K 0.000 description 1
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 1
- MRNLLBXPSWMYCK-UHFFFAOYSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-y Chemical compound N=1C(C=2SC=C(N=2)C(O)=O)=CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C MRNLLBXPSWMYCK-UHFFFAOYSA-N 0.000 description 1
- RZHKDBRREKOZEW-AAXZNHDCSA-N 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl] Chemical compound C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)NC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)C1=CC=CC=C1 RZHKDBRREKOZEW-AAXZNHDCSA-N 0.000 description 1
- BOIPLTNGIAPDBY-UHFFFAOYSA-N 2-[6-(4-chlorophenoxy)hexyl]-1-cyano-3-pyridin-4-ylguanidine Chemical compound C1=CC(Cl)=CC=C1OCCCCCCN=C(NC#N)NC1=CC=NC=C1 BOIPLTNGIAPDBY-UHFFFAOYSA-N 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FFRFGVHNKJYNOV-DOVUUNBWSA-N 3',4'-Anhydrovinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C=C(C2)CC)N2CCC2=C1NC1=CC=CC=C21 FFRFGVHNKJYNOV-DOVUUNBWSA-N 0.000 description 1
- OYTKINVCDFNREN-UHFFFAOYSA-N 3,4-Diaminopyridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 1
- ZZUBHVMHNVYXRR-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-2H-chromen-7-ol Chemical compound C1=CC(O)=CC=C1C1=CC2=CC=C(O)C=C2OC1 ZZUBHVMHNVYXRR-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 1
- ASYYOZSDALANRF-UHFFFAOYSA-K 3-bis[(2-methyl-4-oxopyran-3-yl)oxy]gallanyloxy-2-methylpyran-4-one Chemical compound [Ga+3].CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-] ASYYOZSDALANRF-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ICPOKTZORRQGLK-UHFFFAOYSA-N 3-methylbut-1-ene Chemical group C[C](C)C=C ICPOKTZORRQGLK-UHFFFAOYSA-N 0.000 description 1
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3H-imidazo[4,5-h]quinoline Chemical compound C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
- BTQAFTBKHVLPEV-UHFFFAOYSA-N 3H-naphtho[2,3-e]indazole Chemical compound C1=CC=CC2=CC3=C4C=NNC4=CC=C3C=C21 BTQAFTBKHVLPEV-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- SETFNECMODOHTO-UHFFFAOYSA-N 4-N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 description 1
- YIMDLWDNDGKDTJ-ABYLTEMBSA-N 4-[(2S,3S,4S)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]morpholine-3-carbonitrile Chemical compound N1([C@H]2CC(O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-ABYLTEMBSA-N 0.000 description 1
- YLJOVCWVJCDPLN-UHFFFAOYSA-N 4-[2,2-bis[di(propan-2-yloxy)phosphoryl]ethyl]-2,6-ditert-butylphenol Chemical compound CC(C)OP(=O)(OC(C)C)C(P(=O)(OC(C)C)OC(C)C)CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 YLJOVCWVJCDPLN-UHFFFAOYSA-N 0.000 description 1
- UXXQOJXBIDBUAC-UHFFFAOYSA-N 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 description 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N 4-acetamido-N-(2-aminophenyl)benzamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 1
- JFIWEPHGRUDAJN-DYUFWOLASA-N 4-amino-1-[(2R,3R,4S,5R)-4-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@](O)(C#C)[C@@H](CO)O1 JFIWEPHGRUDAJN-DYUFWOLASA-N 0.000 description 1
- GXAHYXQWHWDEDY-UHFFFAOYSA-N 4-bromo-2-methylpyrazole-3-carbaldehyde Chemical compound CN1N=CC(Br)=C1C=O GXAHYXQWHWDEDY-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- OMJKFYKNWZZKTK-UHFFFAOYSA-N 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)NN=C1N=CN=C1C(N)=O OMJKFYKNWZZKTK-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- YXKRRCXCDMNRAU-UHFFFAOYSA-N 6-[2-(dimethylamino)ethylamino]-5H-indeno[2,1-c]quinoline-3,7-dione Chemical compound C1=CC=C2C(=O)C3=C(NCCN(C)C)NC4=CC(=O)C=CC4=C3C2=C1 YXKRRCXCDMNRAU-UHFFFAOYSA-N 0.000 description 1
- ULDXWLCXEDXJGE-UHFFFAOYSA-N 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one Chemical compound C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 description 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 1
- 229940035620 ACTH and synthetic analog preparations Drugs 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229940022663 Acetate Drugs 0.000 description 1
- 208000004064 Acoustic Neuroma Diseases 0.000 description 1
- 206010000583 Acral lentiginous melanoma Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000002517 Adenoid Cystic Carcinoma Diseases 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 229960001686 Afatinib Drugs 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010817 Alvocidib Drugs 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 229960004701 Amonafide Drugs 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010002224 Anaplastic astrocytoma Diseases 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- MXPOCMVWFLDDLZ-NSCUHMNNSA-N Apaziquone Chemical compound CN1C(\C=C\CO)=C(CO)C(C2=O)=C1C(=O)C=C2N1CC1 MXPOCMVWFLDDLZ-NSCUHMNNSA-N 0.000 description 1
- 229950002465 Apaziquone Drugs 0.000 description 1
- UVJYAKBJSGRTHA-ZCRGAIPPSA-N Arglabin Chemical compound C1C[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2C(C)=CC[C@]32O[C@]31C UVJYAKBJSGRTHA-ZCRGAIPPSA-N 0.000 description 1
- 229940046844 Aromatase inhibitors Drugs 0.000 description 1
- 240000007109 Arundinaria gigantea Species 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N Arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 229950005529 Arzoxifene Drugs 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 206010065869 Astrocytoma, low grade Diseases 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N Atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- QUDMBHHVTODOHM-YXBYCKOISA-N Avicine vaccine Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)[C@@H](C)O)C1=CC=CC=C1 QUDMBHHVTODOHM-YXBYCKOISA-N 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- PEZPMAYDXJQYRV-UHFFFAOYSA-N BBR-2778 Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
- UBJAHGAUPNGZFF-XOVTVWCYSA-N BMS-184476 Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC(C)=O)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OCSC)C(=O)C1=CC=CC=C1 UBJAHGAUPNGZFF-XOVTVWCYSA-N 0.000 description 1
- GMJWGJSDPOAZTP-MIDYMNAOSA-N BMS-188797 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=4C=CC=CC=4)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)OC)C(=O)C1=CC=CC=C1 GMJWGJSDPOAZTP-MIDYMNAOSA-N 0.000 description 1
- 102100015499 BRD2 Human genes 0.000 description 1
- 101700003936 BRD2 Proteins 0.000 description 1
- 102100015498 BRD3 Human genes 0.000 description 1
- 101700008396 BRD3 Proteins 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N Belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 229950011276 Belotecan Drugs 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 108010005144 Bevacizumab Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 108091005571 Bromodomain-containing proteins Proteins 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- RXOVOXFAAGIKDQ-UHFFFAOYSA-N Brostallicin Chemical compound C1=C(C(=O)NCCN=C(N)N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3N(C=C(NC(=O)C(Br)=C)C=3)C)C=2)C)=CN1C RXOVOXFAAGIKDQ-UHFFFAOYSA-N 0.000 description 1
- 229950004271 Brostallicin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N Bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- 229960005064 Buserelin Acetate Drugs 0.000 description 1
- PYMDEDHDQYLBRT-DRIHCAFSSA-N Buserelin acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 PYMDEDHDQYLBRT-DRIHCAFSSA-N 0.000 description 1
- ZIWXKGQDQBLUMV-JUDXGUMMSA-N C(C)(=O)[C@@]1([C@]([C@@](O[C@@H]1CO)(N1C(=O)NC(=O)C=C1)C(C)=O)(O)C(C)=O)O Chemical compound C(C)(=O)[C@@]1([C@]([C@@](O[C@@H]1CO)(N1C(=O)NC(=O)C=C1)C(C)=O)(O)C(C)=O)O ZIWXKGQDQBLUMV-JUDXGUMMSA-N 0.000 description 1
- MDRQCJYXVREJPW-UHFFFAOYSA-N C1=CNC(C2=NNC=C2)=N1 Chemical group C1=CNC(C2=NNC=C2)=N1 MDRQCJYXVREJPW-UHFFFAOYSA-N 0.000 description 1
- 229960005084 CALCITRIOL Drugs 0.000 description 1
- VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 description 1
- 229960002129 CEFIXIME Drugs 0.000 description 1
- NMMGUHANGUWNBN-OGLOGDKOSA-N CEP-751 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1C[C@](OC)(CO)[C@]4(C)O1 NMMGUHANGUWNBN-OGLOGDKOSA-N 0.000 description 1
- 102100000129 CHURC1 Human genes 0.000 description 1
- 101710014631 CHURC1 Proteins 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 102100006435 CSF3 Human genes 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N CTK2H8874 Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108010004480 CTP37 peptide Proteins 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N Canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 1
- 239000005461 Canertinib Substances 0.000 description 1
- 229950002826 Canertinib Drugs 0.000 description 1
- 229950000772 Canfosfamide Drugs 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 210000001011 Carotid Body Anatomy 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N Cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960004755 Ceftriaxone Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229950001357 Celmoleukin Drugs 0.000 description 1
- 229950009017 Cemadotin Drugs 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N Chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 Chloroprocaine Drugs 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N Chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 229960002559 Chlorotrianisene Drugs 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 208000010126 Chondromatosis Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 206010008943 Chronic leukaemia Diseases 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N Cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- 229950009003 Cilengitide Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 229940109275 Cyclamate Drugs 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 229960000978 Cyproterone Acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N Cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N DCM Dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- LRCZQSDQZJBHAF-PUBGEWHCSA-N DHA-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N Decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N Diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 1
- LFQCJSBXBZRMTN-OAQYLSRUSA-N Diflomotecan Chemical compound CC[C@@]1(O)CC(=O)OCC(C2=O)=C1C=C1N2CC2=CC3=CC(F)=C(F)C=C3N=C21 LFQCJSBXBZRMTN-OAQYLSRUSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N Diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 241000668709 Dipterocarpus costatus Species 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N Dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 229950008015 Doranidazole Drugs 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 210000000959 Ear, Middle Anatomy 0.000 description 1
- 229950006595 Edotreotide Drugs 0.000 description 1
- BNFRJXLZYUTIII-UHFFFAOYSA-N Efaproxiral Chemical compound CC1=CC(C)=CC(NC(=O)CC=2C=CC(OC(C)(C)C(O)=O)=CC=2)=C1 BNFRJXLZYUTIII-UHFFFAOYSA-N 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N Elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 Elsamitrucin Drugs 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- 229950009760 Epratuzumab Drugs 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229950000206 Estolate Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 229940012017 Ethylenediamine Drugs 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 229940047887 Etopophos Drugs 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- MVGSNCBCUWPVDA-MFOYZWKCSA-N Exisulind Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)(=O)=O)C=C1 MVGSNCBCUWPVDA-MFOYZWKCSA-N 0.000 description 1
- 206010050497 Eyelid tumour Diseases 0.000 description 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N FOLFIRI regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 Floxuridine Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N Fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960002011 Fludrocortisone Drugs 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N Fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 Fluoxymesterone Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- IWKXDMQDITUYRK-KUBHLMPHSA-N Forodesine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)N[C@H]1C1=CNC2=C1N=CNC2=O IWKXDMQDITUYRK-KUBHLMPHSA-N 0.000 description 1
- 229950011423 Forodesine Drugs 0.000 description 1
- 229960002258 Fulvestrant Drugs 0.000 description 1
- 230000035520 G1 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 229960001731 GLUCEPTATE Drugs 0.000 description 1
- 102100000899 GNRH1 Human genes 0.000 description 1
- 229950011325 Galarubicin Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 108010091266 Gemtuzumab Proteins 0.000 description 1
- UIVFUQKYVFCEKJ-OPTOVBNMSA-N Gimatecan Chemical compound C1=CC=C2C(\C=N\OC(C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UIVFUQKYVFCEKJ-OPTOVBNMSA-N 0.000 description 1
- 229950009073 Gimatecan Drugs 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 229950011595 Glufosfamide Drugs 0.000 description 1
- 229940049906 Glutamate Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 229960003690 Goserelin Acetate Drugs 0.000 description 1
- 229960003727 Granisetron Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N Granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 101710017531 H4C15 Proteins 0.000 description 1
- 101710007269 H4C7 Proteins 0.000 description 1
- 102100007442 H4C7 Human genes 0.000 description 1
- 101700032126 H4Y Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710007262 HHF2 Proteins 0.000 description 1
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 210000003026 Hypopharynx Anatomy 0.000 description 1
- 102100015972 IL2 Human genes 0.000 description 1
- 108010026702 IMC1C11 Proteins 0.000 description 1
- 229940015872 Ibandronate Drugs 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229950009881 Indisulam Drugs 0.000 description 1
- VDJHFHXMUKFKET-WDUFCVPESA-N Ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960003507 Interferon Alfa-2b Drugs 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 229950010897 Iproplatin Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- WVWWZNXKZNACRW-MRQXMKSQSA-N Isohomohalichondrin B Chemical compound O([C@@H]1[C@@H](C)[C@@H]2O[C@@H]3C[C@]4(C[C@@H]5O[C@@]6(O[C@H]7C[C@@H](O)[C@@H](CC(=O)CCO)O[C@H]7[C@@H](C)C6)C[C@@H]([C@@H]5O4)C)O[C@@H]3C[C@@H]2O[C@H]1C[C@@H]1C(=C)[C@H](C)C[C@@H](O1)CC[C@H]1C(=C)C[C@@H](O1)CC1)C(=O)C[C@H](O2)CC[C@H]3[C@H]2[C@H](O2)[C@@H]4O[C@@H]5C[C@@]21O[C@@H]5[C@@H]4O3 WVWWZNXKZNACRW-MRQXMKSQSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229960005280 Isotretinoin Drugs 0.000 description 1
- POADTFBBIXOWFJ-VWLOTQADSA-N Karenitecin Chemical compound C1=CC=C2C(CC[Si](C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 POADTFBBIXOWFJ-VWLOTQADSA-N 0.000 description 1
- KXJTWOGIBOWZDJ-LELJLAJGSA-N L-BLP25 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)[C@@H](C)O)C1=CNC=N1 KXJTWOGIBOWZDJ-LELJLAJGSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940041476 Lactose 100 MG Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 210000000867 Larynx Anatomy 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 206010024218 Lentigo maligna Diseases 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N Lestaurtinib Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229940008250 Leuprolide Drugs 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N Liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N Linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 210000000088 Lip Anatomy 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 229950008991 Lobaplatin Drugs 0.000 description 1
- 229950000909 Lometrexol Drugs 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N Lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 Lurtotecan Drugs 0.000 description 1
- 208000005194 Lymphoma, Large-Cell, Immunoblastic Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010073464 MDX-H210 antibody Proteins 0.000 description 1
- 229950011535 MIVOBULIN Drugs 0.000 description 1
- PBUUPFTVAPUWDE-HSLMEMBISA-N Mafosfamide Chemical compound OS(=O)(=O)CCS[C@@H]1CCOP(=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-HSLMEMBISA-N 0.000 description 1
- 229950000547 Mafosfamide Drugs 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N Marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 Marimastat Drugs 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N Medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 229960004296 Megestrol Acetate Drugs 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960004635 Mesna Drugs 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N Methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N Minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- AARXZCZYLAFQQU-UHFFFAOYSA-N Motexafin gadolinium Chemical compound [Gd].CC(O)=O.CC(O)=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 AARXZCZYLAFQQU-UHFFFAOYSA-N 0.000 description 1
- ISYPMTHOLIXZHJ-UHFFFAOYSA-N Motexafin lutetium Chemical compound [Lu].CC(O)=O.CC(O)=O.C1=NC2=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C2N=CC(C(=C2CCCO)C)=NC2=CC(C(CC)=C2CC)=NC2=CC2=C(CCCO)C(C)=C1N2 ISYPMTHOLIXZHJ-UHFFFAOYSA-N 0.000 description 1
- RGNZALQXJKIZHN-UHFFFAOYSA-N N'-(5-bromo-3-chloropyrazin-2-yl)-2,2,2-trifluoroacetohydrazide Chemical compound FC(F)(F)C(=O)NNC1=NC=C(Br)N=C1Cl RGNZALQXJKIZHN-UHFFFAOYSA-N 0.000 description 1
- QJMCKEPOKRERLN-UHFFFAOYSA-N N,3,4-trihydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-KPKRHBJMSA-N N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl] Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-KPKRHBJMSA-N 0.000 description 1
- URCVCIZFVQDVPM-UHFFFAOYSA-N N-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 URCVCIZFVQDVPM-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N N-ethyl-N-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- SVEUVITYHIHZQE-UHFFFAOYSA-N N-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 210000003928 Nasal Cavity Anatomy 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N Neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N Nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N Nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 229940014995 Nitroglycerin Drugs 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- XHWRWCSCBDLOLM-UHFFFAOYSA-N Nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
- 229950000891 Nolatrexed Drugs 0.000 description 1
- ZQKOGDIJTMNWCT-UFQCMFJCSA-N O=C1CC[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](O)CC(C)[C@H]4[C@@H]3CCC2=C1 Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](O)CC(C)[C@H]4[C@@H]3CCC2=C1 ZQKOGDIJTMNWCT-UFQCMFJCSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 229960002700 Octreotide Drugs 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N Omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 210000003300 Oropharynx Anatomy 0.000 description 1
- 229950001094 Ortataxel Drugs 0.000 description 1
- 208000001715 Osteoblastoma Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 208000003388 Osteoid Osteoma Diseases 0.000 description 1
- 208000008798 Osteoma Diseases 0.000 description 1
- LXCWYTUKZXZSAJ-AUHBJGJSSA-N PCK 3145 Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=C(O)C=C1 LXCWYTUKZXZSAJ-AUHBJGJSSA-N 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 210000003254 Palate Anatomy 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 208000004019 Papillary Adenocarcinoma Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 208000007312 Paraganglioma Diseases 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 210000003695 Paranasal Sinuses Anatomy 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229950006299 Pelitinib Drugs 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- NSIATQGMQRDOCS-NKNBZPHVSA-F Pentasodium samarium (153Sm) N,N,N{{'}},N{{'}}-tetrakis(phosphonatomethyl)ethane-1,2-diamine Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[153Sm].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O NSIATQGMQRDOCS-NKNBZPHVSA-F 0.000 description 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N Perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
- 229950010632 Perifosine Drugs 0.000 description 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 1
- 206010034800 Phaeochromocytoma Diseases 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L Picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- 229950005566 Picoplatin Drugs 0.000 description 1
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 description 1
- KDRKQBMPDQDAJW-UHFFFAOYSA-N Piroxantrone Chemical compound OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCCN KDRKQBMPDQDAJW-UHFFFAOYSA-N 0.000 description 1
- 229960004403 Pixantrone Drugs 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229950001461 Plevitrexed Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N Pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 102000019014 Positive Transcriptional Elongation Factor B Human genes 0.000 description 1
- 108010012271 Positive Transcriptional Elongation Factor B Proteins 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 206010036832 Prolactinoma Diseases 0.000 description 1
- WTHRRGMBUAHGNI-LCYNINFDSA-N Quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 Raloxifene Drugs 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N Ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- INSACQSBHKIWNS-QZQSLCQPSA-N Rebeccamycin Chemical class O[C@@H]1[C@@H](O)[C@H](OC)[C@@H](CO)O[C@H]1N1C2=C3N=C4[C](Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 INSACQSBHKIWNS-QZQSLCQPSA-N 0.000 description 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N Rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 229940089617 Risedronate Drugs 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229950009213 Rubitecan Drugs 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N Rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 101710039253 SEC23B Proteins 0.000 description 1
- 102100001818 SEC23B Human genes 0.000 description 1
- 229950000615 Sabarubicin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000003079 Salivary Glands Anatomy 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N Selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- LVLLALCJVJNGQQ-ZCPUWASBSA-N Seocalcitol Chemical compound C1(/[C@H]2CC[C@@H]([C@@]2(CCC1)C)[C@H](C)/C=C/C=C/C(O)(CC)CC)=C/C=C1/C[C@H](O)C[C@@H](O)C1=C LVLLALCJVJNGQQ-ZCPUWASBSA-N 0.000 description 1
- 229950009921 Seocalcitol Drugs 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- DZMVCVHATYROOS-ZBFGKEHZSA-N Soblidotin Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1 DZMVCVHATYROOS-ZBFGKEHZSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 229950004330 Spiroplatin Drugs 0.000 description 1
- 229950001248 Squalamine Drugs 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960004793 Sucrose Drugs 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N Sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229940034785 Sutent Drugs 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical group OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229950011110 Tacedinaline Drugs 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- SYTBZMRGLBWNTM-SNVBAGLBSA-N Tarenflurbil Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
- 229940063683 Taxotere Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 229950002757 Teoclate Drugs 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- 229960001712 Testosterone Propionate Drugs 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 229950010357 Tetrodotoxin Drugs 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N Tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- 229950006410 Tezacitabine Drugs 0.000 description 1
- GFFXZLZWLOBBLO-ASKVSEFXSA-N Tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 description 1
- 229960003433 Thalidomide Drugs 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- CFBLUORPOFELCE-BACVZHSASA-N Thymectacin Chemical compound N1([C@@H]2O[C@@H]([C@H](C2)O)COP(=O)(N[C@@H](C)C(=O)OC)OC=2C=CC=CC=2)C=C(\C=C\Br)C(=O)NC1=O CFBLUORPOFELCE-BACVZHSASA-N 0.000 description 1
- 208000008732 Thymoma Diseases 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N Tiazofurin Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229950009158 Tipifarnib Drugs 0.000 description 1
- 229950002376 Tirapazamine Drugs 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N Tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- 229950007441 Tocladesine Drugs 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- ZHAKYGFJVGCOAE-UHFFFAOYSA-N Topixantrone Chemical compound OCCNCCN1N=C2C3=CN=CC=C3C(=O)C3=C2C1=CC=C3NCCN(C)C ZHAKYGFJVGCOAE-UHFFFAOYSA-N 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 210000003708 Urethra Anatomy 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- 206010046885 Vaginal cancer Diseases 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229950000578 Vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N Vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 229940058865 Vectibix Drugs 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N Vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N Vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 210000001260 Vocal Cords Anatomy 0.000 description 1
- SXNJFOWDRLKDSF-STROYTFGSA-N Volasertib Chemical compound C1CN([C@H]2CC[C@@H](CC2)NC(=O)C2=CC=C(C(=C2)OC)NC=2N=C3N(C(C)C)[C@@H](C(N(C)C3=CN=2)=O)CC)CCN1CC1CC1 SXNJFOWDRLKDSF-STROYTFGSA-N 0.000 description 1
- 229950003081 Volasertib Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N Vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 210000003905 Vulva Anatomy 0.000 description 1
- 229940053867 Xeloda Drugs 0.000 description 1
- ZPUHVPYXSITYDI-HEUWMMRCSA-N Xyotax Chemical compound OC(=O)[C@@H](N)CCC(O)=O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 ZPUHVPYXSITYDI-HEUWMMRCSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N Zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- IHOVFYSQUDPMCN-XAKVHENESA-N Zosuquidar Chemical compound C([C@H](COC=1C2=CC=CN=C2C=CC=1)O)N(CC1)CCN1C1C2=CC=CC=C2[C@H]2C(F)(F)[C@H]2C2=CC=CC=C12 IHOVFYSQUDPMCN-XAKVHENESA-N 0.000 description 1
- 229950005752 Zosuquidar Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- XMYKNCNAZKMVQN-NYYWCZLTSA-N [(E)-(3-aminopyridin-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=NC=CC=C1N XMYKNCNAZKMVQN-NYYWCZLTSA-N 0.000 description 1
- XASGSSXPZXRXFL-UHFFFAOYSA-L [1-(aminomethyl)cyclohexyl]methanamine;platinum(2+);sulfate Chemical compound [Pt+2].[O-]S([O-])(=O)=O.NCC1(CN)CCCCC1 XASGSSXPZXRXFL-UHFFFAOYSA-L 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- CKXIPXAIFMTQCS-LRDUUELOSA-N [2-[(2S,4S)-4-[(2R,3R,4R,5S,6S)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] 3-aminopropanoate Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)COC(=O)CCN)[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@H]1F CKXIPXAIFMTQCS-LRDUUELOSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- IKDXDQDKCZPQSZ-JHYYTBFNSA-N acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopro Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 IKDXDQDKCZPQSZ-JHYYTBFNSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 201000007538 anal carcinoma Diseases 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic Effects 0.000 description 1
- 230000003432 anti-folate Effects 0.000 description 1
- 230000003388 anti-hormone Effects 0.000 description 1
- 230000000719 anti-leukaemic Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites Pyrimidine analogues Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N azanium;hydron;carbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- CWNBRNSIRVKSDC-UHFFFAOYSA-N azonafide Chemical compound C1=CC=C2C(C(N(CCN(C)C)C3=O)=O)=C4C3=CC=CC4=CC2=C1 CWNBRNSIRVKSDC-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- XIEBQIWVIRKPGE-UHFFFAOYSA-N bicyclo[2.2.0]hex-1(4)-ene Chemical group C1CC2=C1CC2 XIEBQIWVIRKPGE-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- QJBRNNNJBVJKPK-UHFFFAOYSA-N but-1-en-3-yne Chemical group C=[C]C#C QJBRNNNJBVJKPK-UHFFFAOYSA-N 0.000 description 1
- GYKLFBYWXZYSOW-UHFFFAOYSA-N butanoyloxymethyl 2,2-dimethylpropanoate Chemical compound CCCC(=O)OCOC(=O)C(C)(C)C GYKLFBYWXZYSOW-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 108010046713 cemadotin Proteins 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 201000005262 chondroma Diseases 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
- 201000003963 colon carcinoma Diseases 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 108010083340 cryptophycin 52 Proteins 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002100 cyclohexa-1,3-dienyl group Chemical group [H]C1([*])C([H])=C([H])C([H])=C([H])C1([H])[H] 0.000 description 1
- FHEPZBIUHGLJMP-UHFFFAOYSA-N cyclohexene Chemical group [CH]1CCCC=C1 FHEPZBIUHGLJMP-UHFFFAOYSA-N 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- FRGFTUBDLAPOEE-UHFFFAOYSA-N cyclopenta-2,4-dien-1-yl(diphenyl)phosphane;iron(2+);palladium Chemical compound [Fe+2].[Pd].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 FRGFTUBDLAPOEE-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical class O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 235000010300 dimethyl dicarbonate Nutrition 0.000 description 1
- MZGNSEAPZQGJRB-UHFFFAOYSA-N dimethyldithiocarbamic acid Chemical compound CN(C)C(S)=S MZGNSEAPZQGJRB-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 108010045524 dolastatin 10 Proteins 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960000925 efaproxiral Drugs 0.000 description 1
- 229930013349 epothilone B Natural products 0.000 description 1
- 108010007604 epratuzumab Proteins 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- ISJSHQTWOHGCMM-NDEPHWFRSA-N ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](NS(=O)(=O)C=1C(=CC(=CC=1C(C)C)C(C)C)C(C)C)CC1=CC=CC(C(N)=N)=C1 ISJSHQTWOHGCMM-NDEPHWFRSA-N 0.000 description 1
- XXBDOTXPQDVHIP-JTQLQIEISA-N ethyl N-[(2S)-5-amino-2-methyl-3-phenyl-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]carbamate Chemical compound C=1([C@H](C)NC=2C=C(N=C(N)C=2N=1)NC(=O)OCC)C1=CC=CC=C1 XXBDOTXPQDVHIP-JTQLQIEISA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 229950000484 exisulind Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
- 201000010103 fibrous dysplasia Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 201000005160 follicular thyroid carcinoma Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-L galactarate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O DSLZVSRJTYRBFB-DUHBMQHGSA-L 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 201000011626 grade III astrocytoma Diseases 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- AAZSUIZUCQKWPU-UHFFFAOYSA-N hept-1-yne Chemical group [CH2-]CCCCC#[C+] AAZSUIZUCQKWPU-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- LMYQAZODCDGPSE-UHFFFAOYSA-N hexa-1,2,3,4-tetraene Chemical group [CH2+][C]=C=C=C=C LMYQAZODCDGPSE-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002871 immunocytoma Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N iodine atom Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 229930012948 isoflavones Natural products 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000001926 lymphatic Effects 0.000 description 1
- 101700072735 lys-1 Proteins 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- 208000009018 medullary Thyroid cancer Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 201000005962 mycosis fungoide Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000004404 neurofibroma Diseases 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- FKAUINMINWWFBJ-UHFFFAOYSA-N oct-1-en-4-yne Chemical group [CH2-]CCC#CC[C+]=C FKAUINMINWWFBJ-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000010133 oligodendroglioma Diseases 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 108091008124 oncoproteins Proteins 0.000 description 1
- 102000025475 oncoproteins Human genes 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 201000005170 papillary thyroid carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229950007460 patupilone Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- VZCFNJNTQPIJHV-UHFFFAOYSA-N penta-1,2-dien-4-yne Chemical group C=C=[C]C#[C-] VZCFNJNTQPIJHV-UHFFFAOYSA-N 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229930007643 perillyl alcohol Natural products 0.000 description 1
- 235000005693 perillyl alcohol Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- GQONLASZRVFGHI-UHFFFAOYSA-M phenylmagnesium chloride Chemical compound Cl[Mg]C1=CC=CC=C1 GQONLASZRVFGHI-UHFFFAOYSA-M 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 201000007286 pilocytic astrocytoma Diseases 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- FXSKHQLAUMGYJK-UHFFFAOYSA-J platinum(4+);propan-2-amine;dichloride;dihydroxide Chemical compound [OH-].[OH-].[Cl-].[Cl-].[Pt+4].CC(C)N.CC(C)N FXSKHQLAUMGYJK-UHFFFAOYSA-J 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000008520 protoplasmic astrocytoma Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229960005442 quinupristin Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 201000000582 retinoblastoma Diseases 0.000 description 1
- 229960000759 risedronic acid Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- CKNPWBAXEKSCRG-UHFFFAOYSA-J satraplatin Chemical compound CC(=O)O[Pt-2]([NH3+])(Cl)(Cl)(OC(C)=O)[NH2+]C1CCCCC1 CKNPWBAXEKSCRG-UHFFFAOYSA-J 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- LZCVVMQABORALM-UHFFFAOYSA-N spiro[2.5]octyl Chemical group [CH]1CC11CCCCC1 LZCVVMQABORALM-UHFFFAOYSA-N 0.000 description 1
- LMUMMJCCZMWLEN-UHFFFAOYSA-N spiro[3.3]heptyl Chemical group [CH]1CCC11CCC1 LMUMMJCCZMWLEN-UHFFFAOYSA-N 0.000 description 1
- CCOIJUDZGUXWEH-UHFFFAOYSA-N spiro[4.5]dec-2-ene Chemical compound C1C=CCC11CCCCC1 CCOIJUDZGUXWEH-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960001663 sulfanilamide Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 229950010924 talaporfin Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000005161 thyroid carcinoma Diseases 0.000 description 1
- 201000005204 thyroid medullary carcinoma Diseases 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- MHNHYTDAOYJUEZ-UHFFFAOYSA-N triphenylphosphane Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 MHNHYTDAOYJUEZ-UHFFFAOYSA-N 0.000 description 1
- RMFNGLHOFHJMHN-UHFFFAOYSA-L triplatin tetranitrate Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[NH3+][Pt-2]([NH3+])(Cl)[NH2+]CCCCCC[NH2+][Pt-2]([NH3+])([NH3+])[NH2+]CCCCCC[NH2+][Pt-2]([NH3+])([NH3+])Cl RMFNGLHOFHJMHN-UHFFFAOYSA-L 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 201000003761 vaginal carcinoma Diseases 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3 have the meanings given in the claims and in fee specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
Description
This invention relates to compounds of the general formula (I)
R\
wherein the groups R1 to R3 hâve the meanings given in the daims and in the spécification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell prolifération, pharmaceutical préparations containing such compounds and their uses as a médicament. The compounds of the invention are BRD4 inhibitors.
Background of the invention
Histone acétylation is most usually associated with the activation of gene transcription, as the modification loosens the interaction of the DNA and the histone octomer by changing the electrostatics. In addition to this physical change, spécifie proteins bind to acetylated lysine residues within histones to read the epigenetic code. Bromodomains are small (about 110 amino acid) distinct domains within proteins that bind to acetylated lysine résides commonly but not exclusively in the context of histones. There is a family of around 50 proteins known to contain bromodomains, and they hâve a range of fimetions within the cell.
The BET family of bromodomain containing proteins comprises 4 proteins (BRD2, BRD3, BRD4 and BRD-T) which contain tandem bromodomains capable of binding to two acetylated lysine residues in close proximity, increasing the specificity of the interaction. Recent research has established a compelling rationale for targeting BRD4 in cancer. BRD4 remains bound to transcriptional start sites of genes expressed during the entry into the G1 phase of the cell cycle, and is functioning to recruit the positive transcription élongation factor complex (P-TEFb), resulting in increased expression of growth promoting genes (Yang and Zhou, Mol. Cell. Biol. 28, 967, 2008). Importantly, BRD4 has been identified as a component of a récurrent t(l5; 19) chromosomal translocation in an aggressive form of human squamous carcinoma (French et al., Cancer Res. 63, 304, 2003). Such translocations express the tandem N-terminal bromodomains of BRD4 as an in-frame chimera with the NUT (nuclear protein in testis) protein, genetically defining the so-called NUT midline carcinoma (NMC). Functional studies in patient-derived NMC cell lines hâve validated the essential rôle of the BRD4-NUT oncoprotein in maintaining the prolifération and the différentiation block of these malignant cells. In addition, BRD4 has been identified as a critical sensitivity déterminant in a genetically defined AML mouse model (Zuber et al., Nature 2011 478(7370):524-8). Suppression of BRD4 led to robust anti-leukemic effects in vitro and in vivo, accompanied by terminal myeloid différentiation. Interestingly, BRD4 inhibition triggered MYC down-regulation in a broad array of mouse and human leukemia cell lines examined, indicating that small molécule BRD4 inhibitors may provide a means to suppress the MYC pathway in a range of AML subtypes.
Finally, the other family members of the BET family hâve also been reported to hâve some function in controlling or executing aspects of the cell cycle, and hâve been shown to remain in complex with chromosomes during cell division suggesting a rôle in the maintenance of epigenetic memory (Leroy et ai, Mol. Cell. 2008 30(1 ):51-60).
Examples of bromodomain inhibitors are benzodiazépine dérivatives, disclosed in WO2011/054553, and imidazo [4,5] quinoline dérivatives, disclosed in WO2011/054846.
Thus, there is the need to provide BRD4 inhibitors useful for the prévention and/or treatment of diseases characterized by excessive or abnormal cell prolifération, such as cancer.
Detailed description of the invention
The présent invention relates to compounds of formula (I)
R\
wherein,
R1 is -Ci^alkyl or -Ci-shaloalkyl;
R2 is selected from -NHR4, -Ci-salkyl, -Ci.shaloalkyl, halogen and -S-Ci-3alkyl;
β
R is a 5-12 membered heteroaryl, which group is substituted with -X-R10 and 10 optionally further substituted with one ore more groups independently selected from R9;
R4 is selected from -Cj.salkyl and 5-12 memebered heterocycloalkyl, which heterocycloalkyl can be optionally substituted with one or more groups independently selected from R5;
R5 is selected from -Ci-salkyl, -Ci^haloalkyl and -Ci.3alkylene-O-Ci.3alkyl;
R9is selected from-Ci.5alkyl, -O-Ci.5alkyl, -N(Ci.5alkyl)2, halogen, -Ci. 3alkylene-O-Ci.3alkyl, -Ci.5alkylene-N(-Ci.5alkyl, -Ci.5alkyl), 5-12 memebered heterocycloalkyl,wherein the heterocycloalkyl group can be optionally substituted with one or more groups independently selected from =O, -Ci.3alkyl, or
R9 is selected from -Cô-waryl and 5-12 memebered heteroaryl, wherein the aryl and heteroaryl groups can be optionally and independently substituted with one ore more groups selected from halogen, -Ci^alkyl, -O-Ci.jalkyl, -Ci^haloalkyl, -O-Ci^haloalkyl, -N(Ci-5alkyl, Ci^alkyl) and -NH-Ci-salkyl;
X is -Ci.jalkylene- or -O-;
R10 is-Cé-ioaryl or 5-12 membered heteroaryl, each of which groups can be optionally substituted with one or more groups selected from halogen, -Ci-3alkyl, -O-Ci-3alkyl, -Ci^haloalkyl, -O-Ci^haloalkyl;
wherein the compounds of formula (I) may be optionally be présent in the form of salts.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein R1 is -CH3.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein R2 is -NHR4 and R4 is a 5-6 membered heterocycloalkyl, optionally substituted as defined herein in the description and daims.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein R2 is -NHR4 and R4 is tetrahydrofuran or piperidine, wherein the piperidine is substituted with one group selected from -CH3, -CH2CH3, CH2CH2CH3 and -(CH2)2-O-CH3.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein R2 is -NHR4 and R4 is -Ci^alkyl.
In a preferred embodiment, the invention relates to comopunds of formula (I), wherein R2 is -NHR4 and R4 is -CH3 or -CH(CH3)2.
In a preferred embodiment, the invention relates to compounds of formula (I), A wherein R is -Ci-3alkyl.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein R3 is a 5-9 membered heteroaryl substituted with -X-R10 and optionally further substituted with one or more groups independently selected from R9, wherein R9, R10 and X are as defined herein in the description and the claims.
Preferably, R3 is optionally further substituted with one or two R9.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein -X-R10 is selected from -CH2-phenyl, -CH(CH3)-phenyl, -CH2-pyridyl, -CH(CH3)-pyridyl, -O-phenyl, each of which phenyl or pyridyl groups is optionally substituted with -F or -CH3.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein -X-R10 is selected from -CH2-phenyl, -CH2-pyridyl, -CH(CH3)-phenyl, 10 -CH(CH3)-pyridyl, each of which pyridyl or phenyl group is optionally substituted with -F or -CH3.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein R3 is selected from pyrazolyl imidazol, benzimidazolyl, imidazopyridine and imidazopyrimidine and R3 is substituted with -X-R10 and R3 is optionally 15 further substituted with one or more groups independently selected from R9, wherein R9, R10 and X are as defined herein in the description and the claims.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein R9 is independently selected from -C].3alkyl, -O-Ci.3alkyl, -N(C].3alkyl)2, phenyl and 6 membered heterocycloalkyl, which heterocycloalklyl can be 20 optionally substituted with one or more groups independently selected =0 and
-C].3alkyl.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein R3 is imidazopyridine or benzimidazol substituted with -CH2-phenyl or -CH2-pyridyl, -CH(CH3)-pyridyl and optionally further substituted with -Ci.3alkyl 25 or 5-12 memebered heterocycloalkyl wherein the heterocycloalkyl group can be optionally substituted with one or more groups independently selected from -Ci.3alkyl.
In a preferred embodiment, the invention relates to compounds of formula (I), •5 wherein R is imidazopyridine or benzimidazol substituted with -CH2-phenyl, -CH(CH3)-pyridyl or -CH2-pyridyl and substituted with -CH(CH3 )2 or morpholinyl or piperazinyl, wherein the morpholinyl or piperazinyl groups is optionally substituted with one or more groups selected from -Ci-3alkyl.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein the 5-9 membered heteroaryl in R position is attached to the core of the structure via a carbon atom.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein the pyridyl moiety in R10 position is bound to -X- in 2-position.
In a further embodiment, the invention relates to compounds of formula (I) for use in the treatment of cancer.
In a further embodiment, the invention relates to compound of general formula (I) according to anyone of the embodiments described herein in the description and the claims - or the pharmaceutically acceptable salts thereof - for use in the treatment and/or prévention of cancer.
In a further embodiment, the invention relates to pharmaceutical préparation comprising as active substance one or more compounds of general formula (I) according to anyone of the embodiments described herein in the description and the claims optionally in combination with conventional excipients and/or carriers.
In a further embodiment, the invention relates to pharmaceutical préparation comprising a compound of general formula (I) according to anyone of the embodiments described herein in the description and the claims - or one of the pharmaceutically acceptable salts thereof - and at least one other cytostatic or cytotoxic active substance, different from formula (I).
The présent invention further relates to hydrates, solvatés, polymorphs, métabolites, dérivatives and prodrugs of compounds of general formula (I).
The présent invention further relates to a pharmaceutically acceptable sait of a compound of general formula (I) with anorganic or organic acids or bases.
In another aspect the invention relates to compounds of general formula (I) - or the pharmaceutically acceptable salts thereof- as médicaments.
In another aspect the invention relates to compounds of general formula (I) - or the pharmaceutically acceptable salts thereof - for use in a method for treatment of the human or animal body.
In another aspect the invention relates to compounds of general formula (I) - or the pharmaceutically acceptable salts thereof - for use in the treatment and/or prévention of cancer, infections, inflammations and autoimmune diseases.
In another aspect the invention relates to compounds of general formula (I) - or the pharmaceutically acceptable salts thereof - for use in a method for treatment and/or prévention of cancer, infections, inflammations and autoimmune diseases in the human and animal body.
In another aspect the invention relates to compounds of general formula (I) - or the pharmaceutically acceptable salts thereof - for use in the treatment and/or prévention of cancer.
In another aspect the invention relates to the use of the compounds of general formula (I) - or the pharmaceutically acceptable salts thereof-in the treatment and/or prévention of cancer.
In another aspect the invention relates to compounds of general formula (I) - or the pharmaceutically acceptable salts thereof - for use in a method for treatment and/or prévention of cancer in the human or animal body.
In another aspect the invention relates to compounds of general formula (I) - or the pharmaceutically acceptable salts thereof - for use in the treatment and/or prévention of hematopoietic malignancies, preferably AML, MM.
In another aspect the invention relates to compounds of general formula (I) - or the pharmaceutically acceptable salts thereof- for use in the treatment and/or prévention of solid tumors, preferably to lung, liver, colon, brain, thyroid, pancréas, breast, ovary and prostate cancer.
In another aspect the invention relates to a process for the treatment and/or prévention of cancer comprising administering a therapeutically effective amount of a compound of general formula (I) - or one of the pharmaceutically acceptable salts thereof — to a human being.
In another aspect the invention relates to a pharmaceutical préparation containing as active substance one or more compounds of general formula (I) - or the pharmaceutically acceptable salts thereof - optionally in combination with conventional excipients and/or carriers.
In another aspect the invention relates to a pharmaceutical préparation comprising a compound of general formula (I) - or one of the pharmaceutically acceptable salts thereof- and at least one other cytostatic or cytotoxic active substance, different from formula (I).
Définitions
Ternis that are not specifically defined here hâve the meanings that are apparent to the skilled man in the light of the overall disclosure and the context as a whole.
As used herein, the following définitions apply, unless stated otherwise.
In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, -Ci.5alkyl means an alkyl group or radical having 1 to 5 carbon atoms. In general, for groups comprising two or more subgroups, the first named sub-group is the radical attachment point, for example the substitutent -Ci-salkyl-Cs-iocylcoalkyl, means a CAiocylcoalkyl group which is bound to a Cj.salkyl, the latter of which is bound to the core structure or to the group to which the substitutent is attached.
The indication of the number of members in groups that contain one or more heteroatom(s) (heteroalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocycylalkyl) relates to the total atomic number of ail the ring members or chain members or the total of ail the ring and chain members.
The person skilled in the art will appreciate that substituent groups containing a nitrogen atom can also be indicated as amine or amino. Similarly, groups containing oxygen atom can also be indicated with -oxy, like for example alkoxy. Groups containing-C(O)- can also be indicated as carboxy; groups containing -NC(O)- can also be indicated as amide; groups containing -NC(O)N- can also be indicated as urea; groups containing -NS(O)2- can also be indicated as sulfonamide.
Alkyl dénotés monovalent, saturated hydrocarbon chains, which may be présent in both linear and branched form. If an alkyl is substituted, the substitution may take place independently of one another, by mono- or polysubstitution in each case, on ail the hydrogen-carrying carbon atoms.
The term Ci^alkyl includes for example methyl (Me; -CH3), ethyl (Et; -CH2CH3), 1-propyl (π-propyl; π-Pr; -CH2CH2CH3), 2-propyl (z-Pr; wo-propyl; -CH(CH3)2), 1-butyl (π-butyl; n-Bu; -CH2CH2CH2CH3), 2-methyl- 1-propyl (fso-butyl; z-Bu; -CH2CH(CH3)2), 2-butyl (sec-butyl; sec-Bu; -CH(CH3)CH2CH3), 2-methyl-2-propyl (terZ-butyl; Z-Bu; -€(043)3), 1-pentyl (n-pentyl;
-CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 3-methyl- 1-butyl (rio-pentyl; -CH2CH2CH(CH3)2), 2-methyl-2butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 2,2-dimethyl-lpropyl (zzeo-pentyl; -CH2C(CH3)3), 2-methyl- 1-butyl (-CH2CH(CH3)CH2CH3).
By the terms propyl, butyl, pentyl, etc. without any further définition are meant saturated hydrocarbon.groups with the corresponding number of carbon atoms, wherein ail isomeric forms are included.
The above définition for alkyl also applies if alkyl is a part of another group such as for example Cx.y-alkylamino or Cx.y-alkyloxy or Cx.y-alkoxy, wherein Cx.y-alkyloxy and Cx.y-alkoxy indicate the same group.
The term alkylene can also be derived from alkyl. Alkylene is bivalent, unlike alkyl, and reqùires two biriding partners. Formally, the second vàléncy is produced by removing a hydrogen atom in an alkyl. Corresponding groups are for example -CH3 and -CH2, -CH2CH3 and -CH2CH2 or >CHCH3 etc.
The term CM-alkylene includes for example -(CH2)-, -(CH2-CH2)-, -(CH(CH3))-, -(CH2-CH2-CH2)-, -(C(CH3)2)-, -(CH(CH2CH3))-, -(CH(CH3)-CH2)-, -(CH2-CH(CH3))-, -(CH2-CH2-CH2-CH2)-, -(CH2-CH2-CH(CH3))-, -(CH(CH3)-CH2-CH2)-, -(CH2-CH(CH3)-CH2)-, -(CH2-C(CH3)2)-, -(C (CH3)2-CH2)-, -(CH(CH3)-CH(CH3))-, -(CH2-CH(CH2CH3))-, -(CH(CH2CH3)-CH2)-, -(CH(CH2CH2CH3))-, -(CHCH(CH3) 2)- and -C(CH3)(CH2CH3)-.
Other examples of alkylene are methylene, ethylene, propylene, 1 -methylethylene, butylène, 1-methylpropylene, 1.1-dimethyl ethylene, 1,2-dimethyl ethylene, pentylene, 1,1-dimethylpropylene, 2,2-dimethylpropylene, 1,2-dimethylpropylene, 1,3-dimethylpropylene, etc.
By the generic tenus propylene, butylène, pentylene, hexylene etc. without any further définition are meant ail the conceivable isomeric forms with the corresponding number of carbon atoms, i.e. propylene includes 1-methylethylene and butylène includes 1-methylpropylene, 2-methylpropylene, 1,1-dimethylethylene and 1,2-dimethylethylene.
The above définition for alkylene also applies if alkylene is part of another group such as for example in HO-Cx.y-aIkylenamino or H2N-Cx.y-alkyIenoxy.
Unlike alkyl, alkenyl consists of at least two carbon atoms, wherein at least two adjacent carbon atoms are joined together by a C-C double bond. If in an alkyl as hereinbefore defined having at least two carbon atoms, two hydrogen atoms on adjacent carbon atoms are formally removed and the free valencies are saturated to form a second bond, the corresponding alkenyl is formed.
Examples of alkenyl are vinyl (ethenyl), prop-1-enyl, allyl (prop-2-enyl), isopropenyl, but-1-enyl, but-2-enyl, but-3-enyl, 2-methyl-prop-2-enyl, 2-methylprop-l-enyl, l-methyl-prop-2-enyl, 1-methyl-prop-l-enyl, 1-methylidenepropyl, pent-1-enyl, pent-2-enyl, pent-3-enyl, pent-4-enyl, 3-methyl-but-3-enyl, 3-methylbut-2-enyl, 3-methyl-but-l-enyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, hex-5-enyl, 2,3-dimethyl-but-3-enyl, 2,3-dimethyl-but-2-enyl, 2-methylidene-3methylbutyl, 2,3-dimethyl-but-l-enyl, hexa-l,3-dienyl, hexa-l,4-dienyl, penta-1,4dienyl, penta-l,3-dienyl, buta-l,3-dienyl, 2,3-dimethylbuta-l,3-diene etc.
By the generic terms propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, 5 hexadienyl, heptadienyl, octadienyl, nonadienyl, decadienyl etc. without any further définition are meant ail the conceivable isomeric forms with the corresponding number of carbon atoms, i.e. propenyl includes prop-1-enyl and prop-2-enyl, butenyl includes but-1-enyl, but-2-enyl, but-3-enyl, 1-methyl-prop-lenyl, 1 -methyl-prop-2-enyl etc.
Alkenyl may optionally be présent in the cis or trans or E or Z orientation with regard to the double bond(s).
The above définition for alkenyl also applies when alkenyl is part of another group such as for example in Cx.y-alkenylamino or Cxy-alkenyloxy.
Unlike alkylene, alkenylene consists of at least two carbon atoms, wherein at least 15 two adjacent carbon atoms are joined together by a C-C double bond. If in an alkylene as hereinbefore defined having at least two carbon atoms, two hydrogen atoms at adjacent carbon atoms are formally removed and the free valencies are saturated to form a second bond, the corresponding alkenylene is formed.
Examples of alkenylene are ethenylene, propenylene, 1 -methylethenylene, 20 butenyl ene, 1-methylpropenylene, 1,1-dimethyl ethenylene,
1,2-dimethyl ethenylene, pentenylene, 1,1-dimethylpropenylene, 2,2-dimethylpropenylene, 1,2-dimethylpropenylene, 1,3-dimethylpropenylene, hexenylene etc.
By the generic terms propenylene, butenylene, pentenylene, hexenylene etc.
without any further définition are meant ail the conceivable isomeric forms with the corresponding number of carbon atoms, i.e. propenylene includes 1-methylethenylene and butenylene includes 1-methylpropenylene, 2-methylpropenylene, 1,1-dimethylethenylene and 1,2-dimethylethenylene.
Alkenylene may optionally be présent in the cis or trans or E or Z orientation with 30 regard to the double bond(s).
The above définition for alkenylene also applies when alkenylene is a part of another group as in for example HO-Cx.y-alkenylenamino or H2N-Cx.yalkenylenoxy.
Unlike alkyl, alkynyl consists of at least two carbon atoms, wherein at least two 5 adjacent carbon atoms are joined together by a C-C triple bond. If in an alkyl as hereinbefore defined having at least two carbon atoms, two hydrogen atoms in each case at adjacent carbon atoms are formally removed and the free valencies are saturated to form two further bonds, the corresponding alkynyl is formed.
Examples of alkynyl are ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, 10 but-3-ynyl, l-methyl-prop-2-ynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, 3-methyl-but-l-ynyl.
By the generic terms propynyl, butynyl, pentynyl, etc. without any further définition are meant ail the conceivable isomeric fonns with the corresponding number of carbon atoms, i.e. propynyl includes prop-1-ynyl and prop-2-ynyl, 15 butynyl includes but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-l-ynyl, 1 -methyl-prop-2-ynyl.
If a hydrocarbon chain carries both at least one double bond and also at least one triple bond, by définition it belongs to the alkynyl subgroup.
The above définition for alkynyl also applies if alkynyl is part of another group, as 20 in Cx.y-alkynylamino or Cx.y-alkynyloxy, for example.
Unlike alkylene, alkynylene consists of at least two carbon atoms, wherein at least two adjacent carbon atoms are joined together by a C-C triple bond. If in an alkylene as hereinbefore defined having at least two carbon atoms, two hydrogen atoms in each case at adjacent carbon atoms are formally removed and the free 25 valencies are saturated to form two further bonds, the corresponding alkynylene is formed.
Examples of alkynylene are ethynylene, propynylene, 1-methyl ethynyl ene, butynyl ene, 1-methylpropynylene, 1,1-dimethyl ethynyl ene, 1,2-dimethyl12 ethynylene, pentynylene, 1,1-dimethylpropynylene, 2,2-dimethylpropynylene, 1,2-dimethylpropynylene, 1,3-dimethylpropynylene, hexynylene etc.
By the generic tenus propynylene, butynylene, pentynylene, etc. without any further définition are meant ail the conceivable isomeric forms with the con’esponding number of carbon atoms, i.e. propynylene includes 1-methylethynylene and butynylene includes 1 -methylpropynylene, 2-methylpropynylene, 1,1-dimethylethynylene and 1,2-dimethylethynylene.
The above définition for alkynylene also applies if alkynylene is part of another group, as in HO-Cx.y-alkynyleneamino or H2N-Cx.y-aIkynyIeneoxy, for example.
By heteroatoms are meant oxygen, nitrogen and sulphur atoms.
Haloalkyl (haloalkenyl, haloalkynyI) is derived from the previously defined alkyl (alkenyl, alkynyl) by replacing one or more hydrogen atoms of the hydrocarbon chain independently of one another by halogen atoms, which may be identical or different. If a .haloalkyl (haloalkenyl, haloalkynyI) is to be further substituted, the 15 substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on ail the hydrogen-carrying carbon atoms.
Examples of haloalkyl (haloalkenyl, haloalkynyI) are -CF3, -CHF2, -CH2F, -CF2CF3, -CHFCF3, -CH2CF3, -CF2CH3, -CHFCH3, -cf2cf2cf3, -cf2ch2ch3, -CF=CF2, -CC1=CH2, -CBr=CH2, -CI=CH2, -CC-CF3, -CHFCH2CH3,
-CHFCH2CF3 etc.
From the previously defined haloalkyl (haloalkenyl, haloalkynyI) are also derived the terms haloalkylene (haloalkenylene, haloalkynylene). Haloalkylene (haloalkenyl, haloalkynyI), unlike haloalkyl, is bivalent and requires two binding partners. Formally, the second valency is formed by removing a hydrogen atom 25 from a haloalkyl.
Corresponding groups are for exàmplé -CH2F and -CHF-, -CHFCH2F and -CHFCHF- or >CFCH2F etc.
The above définitions also apply if the corresponding halogen groups are part of another group.
Halogen relates to fluorine, chlorine, bromine and/or iodine atoms.
Cycloalkyl is made up of the subgroups monocyclic hydrocarbon rings, bicyclic hydrocarbon rings and spiro-hydrocarbon rings. The Systems are saturated. In bicyclic hydrocarbon rings two rings are joined together so that they hâve at least two carbon atoms together. In spiro-hydrocarbon rings a carbon atom (spiroatom) belongs to two rings together. If a cycloalkyl is to be substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on ail the hydrogen-carrying carbon atoms.
Cycloalkyl itself may be linked as a substituent to the molécule via every suitable position of the ring System.
Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.0]hexyl, bicyclo[3.2.0]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[4.3.0]nonyl (octahydroindenyl), bicyclo[4.4.0]decyl (decahydronaphthalene), bicyclo[2.2.1]heptyl (norbomyl), bicyclo[4.1.0]heptyl (norcaranyl), bicyclo-[3.1 ,l]heptyl (pinanyl), spiro[2.5]octyl, spiro[3.3]heptyl etc.
The above définition for cycloalkyl also applies if cycloalkyl is part of another group as in Cx.y-cycloalkylamino or Cx.y-cycloalkyloxy, for example.
If the free valency of a cycloalkyl is saturated, then an alicyclic group is obtained.
The term cycloalkylene can thus be derived from the previously defined cycloalkyl. Cycloalkylene, unlike cycloalkyl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a cycloalkyl. Corresponding groups are for example cyclohexyl and or or (cyclohexylene).
The above définition for cycloalkylene also applies if cycloalkylene is part of another group as in HO-Cx.y-cycloaIkyleneamino or H2N-Cx.y-cycIoalkyleneoxy, for example.
Cvcloalkenyl is also made up of the subgroups monocyclic hydrocarbon rings, bicyclic hydrocarbon rings and spiro-hydrocarbon rings. However, the Systems are unsaturated, i.e. there is at least one C-C double bond but no aromatic System. If in a cycloalkyl as hereinbefore defined two hydrogen atoms at adjacent cyclic carbon atoms are fonnally removed and the free valencies are. saturated to form a second bond, the corresponding cycloalkenyl is obtained. If a cycloalkenyl is to be substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on ail the hydrogen-carrying carbon atoms. Cycloalkenyl itself may be linked as a substituent to the molécule via every suitable position of the ring System.
Examples of cycloalkenyl are cycloprop-1-enyl, cycloprop-2-enyl, cyclobut-1enyl, cyclobut-2-enyl, cyclopent-1-enyl, cyclopent-2-enyl, cyclopent-3-enyl, cyclohex-1-enyl, cyclohex-2-enyl, cyclohex-3-enyl, cyclohept-1-enyl, cyclohept-2enyl, cyclohept-3-enyl, cyclohept-4-enyl, cyclobuta-l,3-dienyl, cyclopenta-1,4dienyl,. cycto^ cyclopenta-2,4-dienyE:cycl&hexa-lç3^ cyclohexa-l,5-dienyl, cyclohexa-2,4-dienyl, cyclohexa-l,4-dienyl, cyclohexa-2,5dienyl, bicyclo[2.2.1]hepta-2,5-dienyl (norboma-2,5-dienyl), bicyclo[2.2.1]hept-2enyl (norbomenyl), spiro[4.5]dec-2-ene etc.
The above définition for cycloalkenyl also applies when cycloalkenyl is part of another group as in Cx.y-cycloalkenylamino or Cx.y-cycloalkenyloxy, for example. If the free valency of a cycloalkenyl is saturated, then an unsaturated alicyclic group is obtained.
The term cycloalkenylene can thus be derived from the previously defined cycloalkenyl. Cycloalkenylene, unlike cycloalkenyl, is bivalent and requires two binding partners. Formally the second valency is obtained by removing a hydrogen atom from a cycloalkenyl. Corresponding groups are for example
The above définition for cycloalkenylene also applies when cycloalkenylene is part of another group as in HO-Cx.y-cycloalkenyleneamino or H2N-Cx.ycycloalkenyleneoxy, for example.
Aryl dénotés a mono-, bi- or tricyclic group with at least one aromatic carbocycle. Preferably it dénotés a a monocyclic group with six carbon atoms (phenyl) or a bicyclic group with nine or ten carbon atoms (two six-membered rings or one sixmembered ring with a five-membered ring), wherein the second ring may also be aromatic or, however, may also be saturated or partially saturated. If an aryl is to be substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on ail the hydrogen-carrying carbon atoms. Aryl itself may be linked as a substituent to the molécule via every suitable position of the ring System.
Examples of aryl are phenyl, naphthyl, indanyl (2,3-dihydroindenyl), indenyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl (1,2,3,4-tetrahydronaphthyl, tetralinyl), dihydronaphthyl (1,2- dihydronaphthyl), fluorenyl etc.
The above définition of aryl also applies when aryl is part of another group as in arylamino or aryloxy, for example.
If the free valency of an aryl is saturated, then an aromatic group is obtained. The term arylene can also be derived from the previously defined aryl. Arylene, unlike aryl, is bivalent and requires two binding partners. Formally, the second valency is formed by removing a hydrogen atom from an aryl. Corresponding groups are e.g.
The above définition for arylene also applies when arylene is part of another group as in HO-aryleneamino or H2N-aryleneoxy for example.
Heterocyclyl dénotés ring Systems, which are derived from the previously defined cycloalkyl, cycloalkenyl and aryl by replacing one or more of the groups -CH2independently of one another in the hydrocarbon rings by the groups -O-, -S- or -NH- or by replacing one or more of the groups =CH- by the group =N-, wherein a total of not more than five heteroatoms may be présent, at least one carbon atom may be présent between two oxygen atoms and between two sulphur atoms or between one oxygen and one sulphur atom and the ring as a whole must hâve Chemical stability. Heteroatoms may optionally be présent in ail the possible oxidation stages (sulphur -à sulphoxide -SO, sulphone -SO2-; nitrogen -> N-oxide).
A direct resuit of the dérivation from cycloalkyl, cycloalkenyl and aryl is that heterocyclyl is made up of the subgroups monocyclic heterorings, bicyclic heterorings, tricyclic heterorings and spiro-heterorings, which may be présent in saturated or unsaturated form. Saturated and unsaturated, non aromatic, heterocyclyl are also defined as heterocycloalkyl. By unsaturated is meant that there is at least one double bond in the ring System in question, but no heteroaromatic System is formed. In bicyclic heterorings two rings are linked together so that they hâve at least two (hetero)atoms in common. In spiroheterorings a carbon atom (spiroatom) belongs to two rings together. If a heterocyclyl is substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on ail the hydrogen-carrying carbon and/or nitrogen atoms. Heterocyclyl itself may be linked as a substituent to the molécule via every suitable position of the ring system. When the heterocyclyl has a nitrogen atom, the preferred position to bind the heterocyclyl substituent to the molécule is the nitrogen atom.
Examples of heterocyclyl are tetrahydrofuryl, pyrrolidinyl, pyrrolinyl, imidazohdinyl, thiazohdinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, oxiranyl, aziridinyl, azetidinyl, 1,4-dioxanyl, azepanyl, diazepanyl, morphohnyl, thiomorpholinyl, homomorpholinyl, homopiperidinyl, homopiperazinyl, homothiomorpholinyl, thiomorpholinyl-5-oxide, thiomorpholinyl-5,5-dioxide, 1,3-dioxolanyl, tetrahydropyranyl, tetrahydrothiopyranyl, [ 1,4]-oxazepanyl, tetrahydrothienyl, homothiomorpholinylXS-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridyl, dihydro-pyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl-5-oxide, tetrahydrothienyl-X5-dioxide, homothiomorpholinyl-Soxide, 2,3-dihydroazet, 2//-pyrrolyl, 4H-pyranyl, 1,4-dihydropyridinyl,
8-azabicyclo[3.2.l]octyl, 8-azabicyçlo[5.1,0]octyl, 2-oxa-5-azabicyclo[2.2.1 ]heptyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, 3,8-diaza-bicyclo[3.2.1]octyl, 2,5-diazabicyclo-[2.2.1 ]heptyl, 1 -aza-bicyclo[2.2.2]octyl, 3,8-diaza-bicyclo[3.2.1 ]octyl, 3,9-diaza-bicyclo[4.2.1]nonyl, 2,6-diaza-bicyclo[3.2.2]nonyl, l,4-dioxa-spiro[4.5]decyl, l-oxa-3.8-diaza-spiro[4.5]decyl, 2,6-diaza-spiro[3.3]heptyl, 2,7-diaza20 spiro[4.4]nonyl, 2,6-diaza-spiro[3.4]octyl, 3,9-diaza-spiro[5.5]undecyl, 2.8-diazaspiro[4.5]decyl etc.
Further examples are the structures illustrated below, which may be attached via each hydrogen-carrying atom (exchanged for hydrogen):
U Ο
H
Ο
The above définition of heterocyclyl also applies if heterocyclyl is part of another group as in heterocyclylamino or heterocyclyloxy for example.
If the free valency of a heteroyclyl is saturated, then a heterocyclic group is obtained.
The term heterocyclylene is also derived from the previously defined heterocyclyl. Heterocyclylene, unlike heterocyclyl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a heterocyclyl. Corresponding groups are for example
The above définition of heterocyclylene also applies if heterocyclylene is part of another group as in HO-heterocyclyleneamino or H2N-heterocyclyleneoxy for example.
Heteroaryl dénotés monocyclic heteroaromatic rings or polycyclic rings with at least one heteroaromatic ring, which compared with the corresponding aryl or cycloalkyl (cycloalkenyl) contain, instead of one or more carbon atoms, one or more identical or different.heteroatoms, selected independently of one another from among nitrogen, sulphur and oxygen, wherein the resulting group must be chemically stable. The prerequisite for the presence of heteroaryl is a heteroatom and a heteroaromatic System. If a heteroaryl is to be substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on ail the hydrogen-carrying carbon and/or nitrogen atoms. Heteroaryl itself may be Med as a substüuent to the molécule via every suitable position of the ring System, both carbon and nitrogen.
Examples of heteroaryl are füryl, thienyl, pyIrolyl. oxazolyl> thiazolyI> isothiazolyl, pyrazolyl, imidazolyl, tnazolyI. tetrazolyl, oxadlazolyI> ’ pyndyl, pyrimidyl, pyridazinyl, pyrazinyl, «azmy!, p>Tidylw.0XÎdej pyn.oly|.^ ox.de, pynmidmyl-Moxide, pyridazinyl^-oxide, pyrazinylW-oxide, imidazolyl’ isoxazolyW-oxide, oxazolylW-oxide, thiazolylyV-ox.de, oxadiazoIyl-TVoxide, thiadiazolyl-,V-oxide, triazolyl-rV-oxide, tetrazolyl-JV-oxide, indolyl isoindolyl, benzoftryl, benzothienyl, benzoxazolyl, benzothiazoiyl, benzisoxazolyl benzisothiazolyl, benzimidazolyl, indazolyl, isoquinolinyl, quinohnyl quinoxalinyl, cinnolinyl, phthalazinyl, quinazolmyl, benzotriaziny!, indolizmyl oxazolopyndyl, imidazopyridyl, naphthyridinyl, benzoxazolyl, pyridopyridy! punnyl, ptendinyl, benzothiazolyl, imidazopyridyl, imidazothiazolyl, quinolmyWoxide, mdoW-^xide, isoqumo!^^ qui^i,,^^ quinoxaliny,_ 15 TV-oxide, phthalazinylW-oxide, indolizinyl-AT-oxide, indazolyl-W-oxide, benzothiazolyl-A-oxide, benzimidazolylW-oxide etc.
Further examples are the structures ülustrated below, which may be attached via each hydrogen-carrying atom (exchanged for hydrogen):
The above définition of heteroaryl also applies when heteroaryl is part of another group as in heteroarylamino or heteroaryloxy, for example.
If the free valency of a heteroaryl is saturated, a heteroaromatic group is obtained.
The term heteroarylene can therefore be derived from the previously defmed heteroaryl. Heteroarylene, uhlike heteroaryl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a heteroaryl. Corresponding groups are for example
The above définition of heteroarylene also applies when heteroarylene is part of another group as in HO-heteroaryleneamino or H2N-heteroaryleneoxy, for example.
The bivalent groups mentioned above (alkylene, alkenylene, alkynylene etc.) may also be part of composite groups (e.g. H2N-C1 ^alkylene- or HO-Ci.4alkylene-). In this case one of the valencies is saturated by the attached group (here: -NH2, -OH), so that a composite group of this kind written in this way is only a monovalent substituent over ail.
By substituted is meant that a hydrogen atom which is bound directly to the atom under considération, is replaced by another atom or another group of atoms (substituent). Depending on the starting conditions (number of hydrogen atoms) mono- or polysubstitution may take place on one atom. Substitution with a particular substituent is only possible if the permitted valencies of the substituent and of the atom that is to be substituted correspond to one another and the substitution leads to a stable compound (i.e. to a compound which is not converted spontaneously, e.g. by rearrangement, cyclisation or élimination).
Bivalent substituents such as =S, =NR, =NOR, =NNRR, =NN(R)C(O)NRR, =N2 or the like, may only be substituted at carbon atoms, wherein the bivalent substituent =O may also be a substituent at sulphur. Generally, substitution may be carried out by a bivalent substituent only at ring Systems and requires replacement by two geminal hydrogen atoms, i.e. hydrogen atoms that are bound to the same carbon atom that is saturated prior to the substitution. Substitution by a bivalent substituent is therefore only possible at the group -CH2- or sulphur atoms of a ring system.
Stereochemistry/Solvates/HydratesrilMess^tatedOtherwise a structural formula given in the description or in the daims or a Chemical name refers to the corresponding compound itself, but also encompasses the tautomers, stereoisomers, optical and géométrie isomers (e.g. enantiomers, diastereomers, E/Z isomers, etc.), racemates, mixtures of separate enantiomers in any desired combinations, mixtures of diastereomers, mixtures of the forms mentioned hereinbefore (if such forms exist) as well as salts, particularly pharmaceutically acceptable salts thereof. The compounds and salts according to the invention may be présent in solvated form (e.g. with pharmaceutically acceptable solvents such as e.g. water, éthanol etc.) or in unsolvated form. Generally, for the purposes of the présent invention the solvated forms, e.g. hydrates, are to be regarded as of equal value to the unsolvated 5 forms.
Salts: The term pharmaceutically acceptable is used herein to dénoté compounds, materials, compositions and/or formulations which are suitable, according to generally recognised medical opinion, for use in conjunction with human and/or animal tissue and do not hâve or give rise to any excessive toxicity, 10 irritation or immune response or lead to other problems or complications, i.e. correspond overall to an acceptable risk/benefit ratio.
The term pharmaceutically acceptable salts relates to dérivatives of the Chemical compounds disclosed in which the parent compound is modified by the addition of acid or base. Examples of pharmaceutically acceptable salts include 15 (without being restricted thereto) salts of minerai or organic acids in relation to basic functional groups such as for example amines, alkali métal or organic salts of acid functional groups such as for example carboxylic acids, etc. These salts include in particular acetate, ascorbate, benzenesulphonate, benzoate, besylate, bicarbonate, bitartrate, bromide/hydrobromide, Ca-edetate/edetate, camsylate, 20 carbonate, chloride/hydrochloride, citrate, edisylate, ethane disulphonate, estolate, esylate, fiimarate, gluceptate, gluconate, glutamate, glycolate, glycollylarsnilate, hexylresorcinate, hydrabamine, hydroxymaleate, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, malate, maleate, mandelate, methanesulphonate, mesylate, methylbromide, methylnitrate, methylsulphate, mucate, napsylate, nitrate, oxalate, pamoate, pantothenate, phenyl acetate, phosphate/diphosphate, polygalacturonate, propïonate, salicylate, stéarate, subacetate, succinate, sulphamide, sulphate, tannate, tartrate, teoclate, toluenesulphonate, triethiodide, ammonium, benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumin and procaine. Other pharmaceutically acceptable salts may be formed 30 with cations of metals such as aluminium, calcium, lithium, magnésium, potassium, sodium, zinc, etc. (cf. also Pharmaceutical salts, Birge, S.M. et al., J. Pharm. Sci., (1977),66, 1-19).
The pharmaceutically acceptable salts of the présent invention may be prepared starting from the parent compound which carries a basic or acidic functionality, by conventional Chemical methods. Generally, such salts may be synthesised by reacting the free acid or base form of these compounds with a sufficient amount of the corresponding base or acid in water or an organic solvent such as for example ether, ethyl acetate, éthanol, isopropanol, acetonitrile (or mixtures thereof).
Salts of acids other than those mentioned above, which are usefiil for example for purifying or isolating the compounds from the reaction mixtures (e.g. trifluoroacetates), are also to be regarded as part of the invention.
In a représentation such as for example
the letter A has the function of a ring désignation in order to make it easier, for example, to indicate the attachment of the ring in question to other rings.
For bivalent groups in which it is crucial to détermine which adjacent groups they bind and with which valency, the corresponding binding partners are indicated in brackets, where necessary for clarification purposes, as in the following représentations:
(R2)-C(O)NHor (R2)-NHC(O)-;
Groups or substituents are frequently selected from among a number of alternative groups/ substituents with a corresponding group désignation (e.g. Ra, Rb etc). If such a group is used repeatedly to define a compound according to the invention in different molecular parts, it must always be borne in mind that the varions uses are to be regarded as totally independent of one another.
By a therapeutically effective amount for the purposes of this invention is meant a quantity of substance that is capable of obviating symptoms of illness or of preventing or alleviating these symptoms, or which prolong the survival of a treated patient.
List of abbreviations
ACN, CH3CN | acetonitrile |
Boc | /er/.butoxy carbonyl |
DCM | dichloromethane |
DIPEA | diisopropylethyl amine |
DMAP | dimethyl-pyridin-4-yl-amine |
DMF | A.M-dimethylformamidc |
DMSO | dimethylsulphoxide |
EDTA | ethylenediaminetetraacetic acid |
EtOAc or EA | ethyl acetate |
FCS | Fêtai calf sérum |
h | hour(s) |
HATU | N-[(dimethylammo)-(17/-l,2,3-triazolo[4,5-h]pyridin-l-yl)methylenej-A-methylmethan-aminium hexafluorophosphate TV-oxide |
HPLC | high performance liquid chromatography |
KOAc | potassium acetate |
LiHMDS | lithium hcxamcthyl disilazide |
M | Molar |
Min | minute(s) |
mL | Millilitre |
MS | mass spectrometry |
N | Normal |
NMR | nuclear résonance spectroscopy |
PE | petrol ether |
PPh3 | triphenylphosphine |
DIBAL | diisobutylaluminium hydride |
RP | reversed phase |
Rpm | rounds per minute |
RT or rt | room température |
STAB | Sodium triacetoxy borohydride |
TBME | ZerZ.butyl methyl ether |
TEA | triethylamine |
tert | tertiary |
TFA | trifluoroacetic acid |
THF | tetrahydrofuran |
tR | rétention time [min] |
TRIS | tris(hydroxymethyl)aminomethane |
wt% | weight percent |
sat. | Saturated |
Ar | aromatic |
Other features and advantages of the présent invention will become apparent from the following more detailed Examples which exemplarily illustrate the principles of the invention without restricting its scope.
General
Unless stated otherwise, ail the reactions are carried out in commercially obtainable apparatus using methods that are commonly used in Chemical laboratoires. Starting materials that are sensitive to air and/or moisture are stored under protective gas and corresponding reactions and manipulations therewith are carried out under protective gas (nitrogen or argon).
The compounds are named according to the Beilstein rules using the Autonom software (Beilstein). If a compound is to be represented both by a structural formula and by its nomenclature, in the event of a conflict the structural formula is décisive.
Chromatography
Thtn layer chromatography is carried out on ready-made TLC plates of silica gel 60 on glass (with fluorescence indicator F-254) made by Merck.
The préparative high pressure chromatography (HPLC) of the example compounds according to the invention is carried out with columns made by Waters (names: Sunfîre C18 OBD, 10 pm, 30 x 100 mm Part. No. 186003971; X-Bridge C18 OBD, 10 pm, 30 x 100 mm Part. No. 186003930). The compounds are eluted usmg different gradients of H2O/ACN wherein 0.2 % HCOOH is added to the water (acid conditions). For chromatography under basic conditions the water is made basic according to the following recipe: 5 mL of ammonium hydrogen carbonate solution (158 g to 1 L H2O) and 2 ml 32 % ammonia (aq) are made uP to 15 lLwithH2O.
The analytical HPLC (reaction monitoring) of intermediate compounds is carried out with columns made by Waters and Phenomenex. The analytical equipment is also provided with a mass detector in each case.
HPLC mass spectroscopy/UV spectrometry
The rétention times/MS-ESC for charaeterising the example compounds accordtng to the invention are produced using an HPLC-MS apparatus (high performance liquid chromatography with mass detector) made by Agilent. Compounds that elute at the injection peak are given the rétention time tRet = 0.
-5 HPLC-Methods preperative prep. HPLC1
HPLC: 333 and 334 Pumps
Column: Waters X-Bridge Cl8 OBD, 10 pm, 30 x 100 mm,
Part.No. 186003930
Solvent. A. 10 mM NH4HCO3 in H2O; B: Acetonitril (HPLC grade)
Détection: Flow: Gradient: | UV/Vis-155 50 ml/min | ||
0.00 - 1.50 min: 1.50-7.50 min: | 1.5% B varying | ||
5 | prep. HP LC2 HPLC: | 7.50-9.00 min: 333 and 334 Pumps | 100 % B z |
10 | Column: Solvent: | Waters Sunfire Cl 8 OBD, 10 pm, 30 x 100 mm, Part.No. 186003971 A: H2O + 0.2 % HCOOH; B: Acetonitril (HPLC grade) + | |
15 | Détection: Flow: Gradient: | 0.2 % HCOOH UV/Vis-155 50 ml/min 0.00 - 1.50 min: 1.50 - 7.50 min: 7.50 - 9.00 min: | 1.5% B varying 100% B |
HPLC-Methods analytic LCMSBAS1 |
20 HPLC: Agilent 1100 Sériés |
MS: Agilent LC/MSD SL |
Column: Phcnbmenex Mercury Gemini Cl8, 3 pm, 2 x 20 mm, |
Part.No. 00M-4439-B0-CE |
Solvent: A: 5 mM NH4HCO3/20 mM NH3 in H2O; B: Acetonitril |
25 (HPLC grade) |
Détection: MS:Positive and négative mode |
Mass range: 120-900m/z |
Flow: 1.00 ml/min |
Column température: 40 °C |
30 Gradient: 0.00 - 2.50 min: 5 % -> 95 % B |
2.50 - 2.80 min: 95 % B
2.81-3.10 min: 95 % 5 % B
FECB5
HPLC: | Agilent 1100/1200 Sériés |
MS: | Agilent LC/MSD SL |
Column: | Waters X-Bridge Cl8 OBD, 5 pm, 2.1 x 50 mm |
Solvent: | A: 5 mM NH4HCO3/19 mM NH3 in H2O; B: Acetonitril (HPLC grade) |
Détection: | MS:Positive and négative mode |
Mass range: 105- 1200 m/z
Flow: | 1.20 ml/min |
Column température: 35 °C
Gradient: | 0.00 - 1.25 min: 5 % -» 95 % B 1.25 - 2.00 min: 95 % B 2.00-2.01 min: 95 %-> 5 % B |
FECBM3ESI
HPLC: | Agilent 1100/1200 Sériés |
MS: | Agilent LC/MSD SL |
Column: | Waters X-Bridge Cl 8 OBD, 5 pm, 2.1 x 50 mm |
Solvent: | A: 5 mM NH4HCO3/19 mM NH3 in H2O; B: Acetonitril (HPLC grade) |
Détection: | MS:Multimode ESI Positive and négative mode |
Mass range: | 105 — 1200 m/z |
Flow: | 1.20 ml/min |
Column température: 35 °C
Gradient: | 0.00-1.25 min: 5 % 100 % B 1.25-2.00 min: 100% B 2.00 - 2.01 min: 100 % -> 5 % B |
VAB
HPLC: | Agilent 1100/1200 Sériés |
MS: | Agilent LC/MSD SL |
Column: | Waters X-Bridge BEH Cl8, 2.5 pm, 2.1 x 30 mm XP |
Solvent: | A: 5 mM NH4HCO3/19 mM NH3 in H2O; B: Acetonitril (HPLC grade) |
Détection: | MS:Positive and négative mode |
Mass range: | 100- 1200 m/z < . |
Flow: | 1.40 ml/min |
Column température: 45 °C | |
Gradient: FA-8 | 0.00 - 1.00 min: 5 % -> 100 % B 1.00- 1.37 min: 100% B 1.37 - 1.40 min: 100 % -> 5 % B |
HPLC-MS: | Waters - Alliance 2996 |
Column: | Symmetryshield Cl8, 5 pm, 4.6 x 250 mm |
Solvent: | A: H2O + 0.1% TFA; B: Acetonitril (HPLC grade) |
Détection: | MS:Positive-and négative mode |
Mass range: | 100- 1200 m/z |
Flow: | 1.00 ml/min |
Column température: | 25 °C |
Gradient: 2.00- 8.00 min: | 20 % 80 % B |
8.00- 19.00 min: | 80 % B |
19.00-20.00 min: | 80% 20 % B |
FSUN2
HPLC: | Agilent 1100/1200 Sériés |
MS: | Agilent LC/MSD SL |
Column: | Waters Sunfire Cl 8, 5 pm, 2.1 x 50 mm |
Solvent: | A: H2O + 0.2% formic acid; B: Acetonitril (HPLC grade) |
Détection: | MS:Positive and négative mode |
Mass range: | 105- 1200 m/z |
Flow: | 1.20 ml/min |
Column température: 35 °C
Gradient: 0.0 min: 5 % B
0.0 - 1.50 min: 5 % 95 % B
1.50-2.00 min: 95 % B
2.00 - 2.01 min: 95 % 5 % B
Préparation of the compounds according to the invention
The compounds according to the invention are prepared by the methods of synthesis described hereinafter, in which the substituents of the general formula hâve the meanings given hereinbefore. These methods are intended as an illustration of the invention, without restricting its subject matter and the scope of the compounds claimed to these examples. Where the préparation of starting compounds is not described, they are commercially obtainable or may be prepared analogously to known compounds or methods described herein. Substances described in the literature are prepared according to the published methods of synthesis.
Unless otherwise specified, the substituents RI through R3 of the following reaction schemes are as defined in the description and daims.
The synthesis of key intermediate J from startingmaterial A is illustrated in Scheme 1.
Scheme 1 *
H
G
Starting from A, a nucleophilic aromatic substitution reaction can be used to introduce hydrazine B, which leads to C. Compound G can be synthesized applying an amidation reaction with D followed by a bromation with F. After cleavage of the 5 amide and ring closer with an orthoester dérivative I the central intermediate J can be obtained.
The synthesis of compounds of formula I - III from key intermediate J is illustrated in Scheme 2.
Scheme 2
Residue R2 can be introduced via a nucleophilic aromatic substitution reaction using the corresponding amine, alcohol, thiol or a carbo nucleophile (e.g.
diethylmalonate) to produce intermediate K.
Final compounds I were synthesized starting from intermediate K and applying a Suzuki reaction with boronic acids L.
Intermediate M, which is synthesized from K using a palladium catalyzed carbonylation reaction, is the central intermediate for final compounds II and III.
Intermediate M was condensed with aromatic/heteroaromatic diamines Q resulting in final compounds III.
Réduction of the acid of M and re oxidation of the corresponding alcohol lead to intermediated N, which is condensed with oxime O and amine P to final compounds II.
Préparation of intermediate J-l
6-bromo-8-chloro-3-methyl-[I,2,4]triazol<i|4,3-a]pyrazine J-l
Reaction scheme:
^NH, H?N 2
B-1
EtOH, 25 °C (yield: 75 %)
(yield: 100 %)
Br F-1
E-1 (yield: 13 %)
DCM; -40 °C
2-chIoro-3-hydrazinylpyrazine C-l
H ; |p NH2 TT^CI
2,3-DichIoropyrazine A-l (15 g; 100.68 mmol) and hydrazine hydrate 65 % (15.509 ml; 201.37 mmol) are dissolved in 45 ml éthanol and stirred for 1 h at 80 °C. While cooling down, a precipitate is formed. It is slurred up with a small amount of water and filtered off. It is washed with water and then dried to afford the product.
Yield: 93% (13.6 g; 94.07mmol)
HPLC-MS: (M+H) = 145/147; tRet = 0.34 min; method FECB5
N'-(3-chloropyrazin-2-yl)-2,2,2-trifluoroacetohydrazide E-l
2-Chloro-3-hydrazinylpyrazine C-l (15.6 g; 108 mmol) is slurried up in (300 ml) THF and cooled down in an ice bath to -5 °C. Trifluoroacetic anhydride (17 ml; 118 mmol) is also dissolved in 300 ml THF and dropped slowly to the First solution. After 1 h most of the THF is evaporated, than a small amount of water is added and the mixture is extracted with DCM. The organic phase is dried over MgSO4 and evaporated to dryness.
Yield: 100 %
HPLC-MS: (M+H)+ = 241/243; tRet =1.31 min; method FSUN2
N'-(5-bromo-3-chloropyrazin-2-yl)-2,2,2-trifIuoroacetohydrazide G-l
O
N'-(3-chloropyrazin-2-yl)-2,2,2-trifluoroacetohydrazide E-l (19,5 g; 81.1 mmol) is dissolved in 300 ml anhydrous DCM and cooled down to - 40 °C. Afterwards NBS (18.8 g; 105 mmol) is added and stirred for .l hour. The solution is diluted with water and extracted with DCM. The organic phase is then purified with flash chromatography: cHex/(EtOAc/CH3COOH= 9/1) = 80% / 20% to 70% / 30% within 10 column volumes.
Yield: 11% (2.83 g; 8.859 mmol)
HPLC-MS: (M-H)’ = 317/319/321; tRet = 1.79 min; method FSUN2
3S
5-bromo-3-chloro-2-hydrazmyIpyrazine H-l
H if Y NH2
N'-(5-bromo-3-chloropyrazin-2-yl)-2,2,2-trifluoroacetohydrazide G-l (1.59 g;
4.97 mmol) is dissolved in 30 ml EtOH and treated with 3 ml conc. HCl. It is stirred for 2 hours at 100 °C. The reaction mixture is cooled down, diluted with water and then the pH adjusted to 8 with saturated NaHCO3 solution. The water phase is extracted with EtOAc, the organic layer dried over MgSO4 and evaporated to dryness.
Yield:71 % (945 mg; 3.51 mmol)
HPLC-MS: (M-H)‘ = 221/223/225; tRet = 1.32 min; method FECB5
6-bromo-8-chIoro-3-methyl-[l,2,4]triazolo[4,3-a]pyrazine J-l
5-bromo-3-chloro-2-hydrazinylpyrazine H-l (945 mg; 3.51 mmol) is dissolved in 12 ml trimethyl orthoacetate and heated up to 130 °C for 1 hour. The solution is diluted with water and extracted with EtOAc. The organic phase is then purified with flash chromatography: cHex/EtOAc = 70% / 30% to 55% / 45% within 10 column volumes.
Yield: 71% (824 mg; 3.33 mmol)
HPLC-MS: (M+H)+ = 247/249/251; tRet = 1.23 min; method FECB5
Préparation of intermediate K-l tert-butyl 4-({6-bromo-3-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8yl}amino)piperidine-l-carboxylat
6-bromo-8-chloro-3-methyl-[l,2,4]triazolo[4,3-a]pyrazine J-l (3.24 g; 13.1 mmol), 4-amino-l-boc-piperidine (5.24 g; 26.2 mmol) and hünigbase (2.44 ml; 14.4 mmol) are dissolved in 30 ml THF and are stirred for 16 hours at 25 °C. The reaction mixture is diluted with water and extracted with EtOAc. The organic layer is separated and dried over MgSC>4 and evaporated to dryness.
Yield: 98 % (6.60 g; 12.8 mmol)
HPLC-MS: (M+H) = 411/413; tRet = 0.88 min; method VAB
Préparation of intermediate K-3
6-bromo-3,8-dimethyI-[l,2,4]triazolo[4,3-a]pyrazine K-3
Caesiumcarbonate (7ώ5 g; 22.3 mmol) is suspended in 5 ml NMP. To this suspension di-tert-butyl malonate (4.80 g; 22.3 mmol) is added and the resulting 15 mixture is.stirred for 30 min at 25 °C. Finally ô-bromo-S-chloro-j-methyl[l,2,4]triazolo[4,3-a]pyrazine J-l (1.00 g; 4.04 mmol) is added and the reaction mixture is stirred for 18 h at 25 °C. The reaction mixture is treated with aqueous 1 N HCl until the pH value is below 5 and then extracted with DCM. The organic layer is separated and dried over MgSÛ4 and is evaporated to dryness.
The crude intermediate is purified using reverse phase chromatography (method prep. HPLC2). The intermediate is dissolved in 5 ml DCM and 5 ml TFA and stirred for 16 h at 40 °C. The reaction mixture is evaporated and the crude product is purified using reverse phase chromatography (method prep. HPLC2).
Yield: 15 % (138 mg; 0.61 mmol)
HPLC-MS: (M+H)+ = 227/229; tRet = 0.47 min; method VAB
According to the procedures of K-l and K-3 the intermediates K-2 are synthesized.
MS (M+H)+; HPLCtRet. HPLC [min]Method
Y=N / \ | |||
K-2 | M+H=242/244; | ||
Λ X Βγ^Ή^ΉΗ | tRet.= 0.59 | V ÆO | |
K-3 | M+H=227/229; | VAB | |
X X Br^N^- | ÎRet.= 0.47 | ||
\=N / \ | |||
K-4 | N ZzN Xl Br N NH | M+H=256/258; tRet = 0.64 | VAB |
K-5 | Îi 1 | M+H=270/272; | VAB |
II J Br N NH | ÎRet = θ·69 | ||
\=N / \ | |||
K-6 | N ZzN il ΒΓΉ NH | M+H=298/300; | VAB |
ό |
Préparation of intermediate M-l
8-({l-[(tert-butoxy)carbonyl]piperidin-4-yl}amino)-3-methyI[l,2,4]triazoIo[4,3-a]pyrazine-6-carboxy!ic acid M-l
tert-butyl4-({6-bromo-3-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8yl}amino)piperidine-l-carboxylat K-l (1.85 g; 3.59 mmol), dichloro[l,l’bis(diphenylphosphino)ferrocene] palladium (II) dichlormethane adduct (310 mg, 0.38 mmol) and triethylamine (910 mg; 8.99 mmol) are dissolved in 10 ml methanol and 10 ml NMP. The reaction mixture is stirred for 3 h at 70°C and 2 bar CO pressure. The reaction mixture is diluted with water and extracted with EtOAc. The organic layer is separated and dried over MgSO4 and evaporated to dryness. The crude product is purified using method prep. HPLC1. This intermediate is dissolved in 20 ml THF and is treated with 10 ml of a 1 N aqueous LiOH solution. After 1 h the reaction mixture is diluted with water and extracted with DCM. The organic layer is separated and dried over MgSO4 and evaporated to dryness. Yield: 72 % (976 mg; 2.59 mmol) HPLC-MS: (M-H)’ = 375; tRet = 0.88 min; method FECB5
According to the procedures of M-l the intermediates M-2 and M-3 are synthesized.
MS (M+H)+; HPLCtRet, HPLC [min] Method
M+H=208; WA1,
0.0 VAB
Structure
MS (M+H)+; tRet. HPLC [min]
HPLCMethod
M-3
M+H=193; tRet = 0.0
M-4
M+H=222;
tRet= 0.0
VAB
M-5
M-6
M+H=236; tRet = 0.0
M+H=264; tRet = 0.0
VAB
VAB
Préparation of intermediate L-l (l-methyl-5-phenoxy-lH-pyrazol-4-yl)boronic acid
l-Methyl-5-phenoxy-lH-pyrazole-4-carboxylic acid ethyl ester
Phénol (30.3 g; 322 mmol) is dissolved in DMA and K2CO3 (88.9 g; 643 mmol) is added portion wise. It is stirred for 10 minutes, then 5-Bromo-l-methyl-lHpyrazole-4-carboxylic acid ethyl ester (50.0 g; 215 mmol) is dropped to the reaction mixture and heated up to 140 °C for 16 hours. A 10 % ci trie acid solution is added and extracted with DCM. The organic layer is washed with sodium bicarbonate and brine, then dried and purified through column chromatography.
Yield: 43 % (22.5 g; 91.37 mmol)
HPLC-MS: (M+H)+ = 247; tRet = 3.50 min; method LCMS FA-8 l-Methyl-5-phenoxy-lH-pyrazoIe-4-carboxylic acid o
l-Methyl-5-phenoxy-lH-pyrazole-4-carboxylic acid ethyl ester (22.6 g;
91.4 mmol) is dissolved in THF/MeOH (1/1) and LiOH in water (7.67 g;
183 mmol) is added. After 16 hours at ambient température the reaction mixture is washed with EtOAc. The aqueous layer is acidified with 1 N HCl and extracted with EtOAc. The organic layer is dried and evaporated.
Yield: 80 % (16.0 g; 73.3 mmol)
HPLC-MS: (M+H)+ = 219; tRet = 2.88 min; method LCMS FA-8 l-Methyl-5-phenoxy-lH-pyrazol-4-ylamine
To a stirred mixture of l-Methyl-5-phenoxy-lH-pyrazole-4-carboxylic acid (16.0 g; 73.3 mmol), t- BuOH (51.2 g; 691 mmol) in 1,4-dioxane under argon are added DIPEA (37.4 g ; 290 mmol) and diphenylphosphoryl azide (41.6 g;
151 mmol). After 10 minutes at ambient température it is heated up to 110 °C and stirred for 3 hours. The solvent is evaporated and the crude material purified by column chromatography. This compound is dissolved in DCM and treated with
M HCl in 1,4-dioxane. It is stirred for 2 days at ambient température. The solvent is evaporated and the residue dissolved in water and washed with EtOAc. The aqueous layer is basified with aqueous NaHCO3 solution and is extracted with EtOAc. The organic layer is dried and concentrated to dryness.
Yield: 32 % (16.0 g; 73.3 mmol)
HPLC-MS: (M+H)+ = 190; tRet = 2.32 min; method LCMS FA-8
4-Iodo-l-methyl-5-phenoxy-lH-pyrazole
l-Methyl-5-phenoxy-lH-pyrazol-4-ylamine (4.50 g; 23.8 mmol) is dissolved in H2SO4 and cooled to 0 °C. NaNO2 (1.64 g; 23.8 mmol) is dissolved in water and is added to the reaction mixture. It is stirred for 1 hour at 0 °C then Kl (15.8 g;
95.1 mmol) is added whilst vigorous stirring and warming up to ambient température within 30 minutes. It is treated with water and neutralized with saturated NaHCO3 solution. The water layer is extracted with DCM, dried and purified by column chromatography.
Yield: 38 % (2.70 g; 8.99 mmol)
HPLC-MS: (M+H)+ = 301; tRet = 3.74 min; method LCMS FA-8 (l-methyl-5-phenoxy-lH-pyrazol-4-yl)boronic acid
HO^ /OH B
4-Iodo-l-methyl-5-phenoxy-lH-pyrazole (862 mg; 2.75 mmol) is dissolved in ml THF extra dry and cooled down to -78 °C. Afterwards n-BuLi (1.80 ml;
2.88 mmol; 1.6 mol/1 in Hexane) and Triisopropyl borate (982.28 mg; 5.22 mmol) are added. It is stirred for 1 hour. The reaction mixture is quenched with 1 ml water and purified with reversed phase chromatography under basic conditions.
Yield: 67 % (400 mg; 1.84 mmol)
HPLC-MS: (M+H)+ = 219; tRet = 1.34 min; method FECB5
Préparation of intermediate L-2 (5-benzyl-l-methyl-lH-pyrazol-4-yl)boronic acid
OH
I
(4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl-methanol
N-N
4-Bromo-2-methyl-2H-pyrazole-3-carbaldehyde (1.00 g; 5.29 mmol) is dissolved in 5.0 ml of anhydrous THF and cooled down to - 78 °C. Phenylmagnesium chloride 2 mol/1 (6.61 ml; 13.2 mmol) is added and the reaction mixture is stirred for 1 hour. It is warmed up to 0 °C and is quenched carefully with water, then extracted with DCM. The organic layers are pooled, dried over MgSO4 and purified by using reversed phase chromatography under basic conditions.
Yield: 82 % (1.16 g; 4.35 mmol)
HPLC-MS: (M+H)+ = 267; tRet = 1.59 min; method FECBM3ESI
5-Benzyl-4-bromo-l -methyl-1 H-pyrazole
N-N (4-Bromo-2-methyl-2H-pyrazol-3-yl)-phenyl-methanol (0.50 g; 1.87 mmol) is treated with 3.0 ml TFA and Triethylsilane (1.49 ml; 9.36 mmol) and is heated to 50 C for 16 hours. The product is purified via reversed phase chromatography under acid conditions.
Yield: 56 % (0.26 g; 1.06 mmol)
HPLC-MS: (M+H)+ = 251/253; tRet = 1.71 min; method FECBM3ESI (5-benzyl-l-methyl-lH-pyrazol-4-yl)boronic acid
OH
I
5-Benzyl-4-bromo-l -methyl-1 H-pyrazole (0.27 g; 1.06 mmol) is dissolved in
5.0 ml anhydrous THF and cooled down to — 78 °C. Afterwards triisopropyl borate (0.46 ml; 2.01 mmol) and n-BuLi; 1,6 mol/1 in Hexane; (0.69 ml; 1.11 mmol) are added. It is stirred for 1 hour within the desired product is formed. It is warmed to 25 °C and quenched with water. It is purified with reverse phase chromatography by using basic conditions.
Yield: 39 % (0.08 g; 0.41 mmol)
HPLC-MS: (M+H)+ = 217; tRet = 1.41 min; method FECBM3ESI
Préparation of intermediate L-5 (5-benzyl-l-methyl-lH-pyrazol-4-yl)boronic acid - L-5
Reaction Scheme:
L-5-1
L-5-2 L-5-3
L-5 L-5-4
Intermediate L-5-4 is synthesized according to the procedures described in Bioorganic & Med. Chem. Letters 18(2) 509-512 2008. For the synthesis of the boronic acid L-5 the procedures described for L-l and L-2 are used.
HPLC-MS: (M+H)+ = 233; tRet = 0.73 min; method VAB
According to the procedures of L-l and L-2 the intermediates L-3 and L-4 are synthesized.
MS (M+H)1
Structure tRet. HPLC HPLC-Method
L-4
M+H=231; tRet = 0-76
VAB
General method for préparation of compounds of formula I
6-(3-benzyl-l-methyl-lH-pyrazol-4-yl)-N,3-dimethyl-[l,2,4]triazolo[4,3a]pyrazin-8-amine 1-1
Intermediate G-2 (32 mg; 0.13 mmol), boronic acid L-3 (30 mg; 0.13 mmol), Cs2CO3 70 % solution in water (0.05 ml; 0.25 mmol) and Pd[P(t-Bu)3]2 (5 mg; 0.01 mmol) are suspended with THF/NMP = 2/1 (0.3 ml) and flushed with argon. It * 'X is stirred at 90 °C for 1 hour. The crude reaction mixture is purified by using reversed phase chromatography under acid conditions (Method: prep. HPLC2). Yield: 33 % (0.02 g; 0.04 mmol)
HPLC-MS: (M+H)+ = 417; tRet = 1.05 min; method LCMSBAS1
According to 1-1 the following examples are synthesized.
M+H= 347; tRet.= 1.11
LCMSBAS1
MS (M+H)+; tRet. HPLC [min]
M+H= 34.9;. tRet = 1.12
HPLC-Method
LCMSBASl
General method for préparation of compounds of formula II
6-(l-benzyl-5-methyl-4-phenyl-lH-imidazoI-2-yl)-N,3-dimethyl[1,2,4] triazolo [4,3-a] pyrazin-8-amine II-1
3-methyl-8-(methylamino)-[l,2,4]triazolo[4,3-a]pyrazine-6-carbaldehyde
3-methyl-8-(methylamino)-[l,2,4]triazolo[4,3-a]pyrazine-6-carboxylic acid M-2 (300 mg; 1.45 mmol) is dissolved in 2 ml THF and is treated with 1 M borane-THF complex (4 ml; 4.00 mmol). The reaction mixture is stirred for 16 h at 50 °C.
Afterwards the reaction mixture is cool down to 0°C and 1 N aqueous HCl is added until the pH values is less than 7.
It is diluted with DCM, the organic lays is separated and dried over MgSO4. The crude product is purified by using reversed phase chromatography (Method: prep. HPLC1). This intermediate is suspended in 20 ml Chloroform and treated with manganèse dioxide (350 mg; 4.07 mmol). The reaction mixture is stirred for 4 days at 50 °C. Afterwards the solid material is filtered oif and.the solvent is evaporated. Yield: 16 % (44 mg; 0.23 mmol)
HPLC-MS: (M+H)+ = 192; tRet = 0.52 min; method FECB5
6-(l-benzyI-5-methyI-4-pheïiyl-lH-imidazol-2-yl)-N,3-dimethyl[l,2,4]triazolo[4,3-a]pyrazin-8-amine II-l
3-Methyl-8-methylamino-[l,2,4]triazolo[4,3-a]pyrazine-6-carbaldehyde (34 mg; 0.18 mmol), benzylamine (20 μΐ; 0.18 mmol) and 1-hydroxyimino-l-phenyl propan-2-one (32 mg; 0.18 mmol) are dissolved in 0.6 ml acetic acid stirred for 2 h at 120°C. The reaction mixture is treated with water and extracted with DCM. The organic layer is dried over MgSO4 and evaporated to dryness. The crude intermediate is dissolved in 20 ml of THF and treated with Ra-Ni. The reaction mixture is stirred for 2 days at 25°C and 4 bar hydrogen atmosphère. The solid materials are filtered off and the crude product is purified using reversed phase chromatography (Method: prep. HPLC1).
Yield: 33 % (25 mg; 0.06 mmol)
HPLC-MS: (M+H)+ = 410; tRet =1.17 min; method LCMSBAS1
According to II-1 the following examples are synthesized.
# Structure M® ! HPLC-Method tRet. HPLC [min]
II-2
II-3
M+H= 348; tRet = 1.09
M+H= 333; tRet = LU
LCMSBAS1
LCMSBAS1
Préparation of intermediate Q-6
N-4-Benzyl-6-(4-methyl-piperazin-l-yl)-pyridme-3,4-diamine Q-6
2,4-Dichloro-5-nitro-pyridine (250 mg; 1.29 mmol), benzylamine (153 μΐ;
1.42 mmol) and DIPEA (314 μΐ; 1.94 mmol) are suspended in 1 ml NMP and stirred for 1 h at 25 °C. To this suspension 1-methylpiperazine (159 μΐ; 1.43 mmol) is added and the resulting mixture is stirred for 16 h at 50 °C. The crude intermediate is purified using reversed phase chromatography (prep. HPLC). This intermediate is dissolved in 30 ml THF and palladium on carbon is added. The reaction mixture is stirred for 3 h at 25 °C and 4 bar hydrogen pressure. The solid material is filtered off and the solvent is evaporated.
Yield: 48 % (184 mg; 0.62 mmol)
HPLC-MS: (M+H)+ = 298; tRet = 0.68 min; method VAB
Préparation of intermediate Q-29
6-(propan-2-yl)-4-N-(pyridin-2-yimethyl)pyridine-3,4-diamine
2,4-Dichloro-5-nitro-pyridine (500 mg; 2.46 mmol), pyridine-2-yl-methylamine (260 μΐ; 2.49 mmol) and triethylamine (400 μΐ; 2.82 mmol) are suspended in 1 ml NMP and stirred for 1 h at 25 °C. The reaction mixture is diluted with water and the precipitate is filltered off, washed with water and methanol and dried.
Yield: 87 % (566 mg; 2.14 mmol)
This intermediate (125 mg, 0.47 mmol), 2-Isopropenyl-4,4,5,5-tetramethyl[l,3,2]dioxaborolane (200 μΐ; 1.06 mmol), Cs2CO3 (300 mg; 0.90 mmol) and Pd DPPF (30 mg; 0.04 mmol) are suspended with l,2dimethoxyethane/water = 3/1 (10 ml) and flushed with argon. It is stirred at 95 °C for 1 hour. The crude reaction 5 mixture is purified by using reversed phase chromatography under basic conditions (Method: prep. HPLC1).
Yield: 43 % (55 mg; 0.20 mmol)
This intermediate (40 mg, 0.15 mmol) is dissolved in 10 ml methanol and palladium on carbon is added. The reaction mixture is stirred for 3 h at 25 °C and 4 bar hydrogen pressure. The solid material is filtered off and the solvent is evaporated.
Yield: 95 % (35 mg; 0.14 mmol)
HPLC-MS: (M+H)+ = 242; tRet = 0.68 min; method VAB
According to the procedures of Q-6 and Q-29 the intermediates Q-l - Q-39 are synthesized.
Q-i
Q-2
Q-3
MS (M+H)+; HPLCtRet, HPLC [min]_____Method commercial available
M+H=213; tRet = 1-96
M+H=213; tRet.= 1.96
FECB5
FECB5
Q-5
F
M+H=217; tRet.= 0-87 | VAB |
M+H=235; | \7 Λ TD |
tRet = 0.89 | V Ad |
M+H=298; tRet = 0.68 | VAB |
M+H=200; | VAD |
tRet = 0.69 | V Aid |
M+H=299; | \7 Λ T5 |
tRet =0.71 | V Ajd |
M+H=284; tRet= 0.76 | VAB |
M+H=297; tRet = 1-54 | FECB5 |
Structure
MS (M+H)+; tRet. HPLC [min]
HPLCMethod
Q-ll
Q-12
Q-13
Q-14
Q-15
Q-16
M+H=309; tRet = 1 -63
M+H=313; tRet- 0.80
M+H=299; tRet= 1-30
M+H=286;
tRet.= 0.56
M+H=285; tRet= 0.78
M+H=284; tRet.= 0.72
MS (M+H)+;
ÎRet. HPLC [min]
M+H=304;
ÎRet = θ·63
M+H=300; tRet = 0.66
M+H=300; tRet= 0-66
M+H=244; tRet= 0.59
M+H=243; tRet = 0.77
M+H=200; tRet.= 0.70
M+H=230;
tRet = 1-44
HPLCMethod
VAB
VAB
VAB
FECB5
MS (M+H)+; tRet. HPLC [min]
M+H=214; tRet.^ 0.76
M+H=215; tRet = 0.20
M+H=201; tRet = 0.52
M+H=300; tRet= 0.63
M+H=231;
tRet = 0.62
M+H=243; tRet = 0.68
M+H=3l4; tRet= 1.40
HPLCMethod
VAB
VAB
VAB
VAB
VAB
VAB
FECB5
MS (M+H)+;
tRet. HPLC [min]
M+H=257;
ÎRet = 0-72
M+H=285; tRet= 0-54
M+H=284; tRet = 0-73
M+H=298; tRet = 0-76
M+H=256; tRet = θ·89
M+H=299; tRet~ 1-26
M+H=298; tRet= 0-57
HPLCMethod
VAB
VAB
VAB
VAB
VAB
FECB5
VAB
MS (M+Hf; tRet. HPLC [min]
M+H=286; tRet = 0-54
M+H=285; tRet = 0-59
M+H=215;
ÎRet = 1 -24
M+H=299; tRet.= 0.55
HPLCMethod
VAB
VAB
General method for préparation of compounds of formula III
N-[6-(l-benzyl-lH-l,3-benzodiazol-2-yl)-3-methyl-[l,2,4]triazolo[4,3a] pyr azin-8-yl] -1 -methylpiperidin-4-amine III-1
N-[6-(l-benzyl-lH-l,3-benzodiazol-2-yl)-3-methyl-[l,2,4]triazolo[4,3a] pyrazin-8-yl] piperidin-4-amine
8-( {1 -[(tert-butoxy)carbonyl]piperidin-4-yl} amino)-3-methyl-[1,2,4]triazolo[4,3a]pyrazine-6-carboxylic acid M-l (238 mg; 0.63 mmol), Hünigbase (306 μΐ;
1.89 mmol) and HATU ( 264 mg; 0.69 mmol) are dissolved in 2 ml DMF. The reaction mixture is stirred for 10 min, then N-benzyl-l,2-diaminobenzene Q-l (138 mg; 0.69 mmol) is added and the resulting mixture is stirred for an additional
1 h at 25 °C. The reaction mixture is diluted with water and DCM. The organic layer is separated and dried over MgSO4 and the solvent is evaporated. The crude intermediate is dissolved in 4 ml acetic acid and stirred at 100 °C for 3 h.
Afterwards the reaction mixture is neutralized with aqueous NaHCO3 solution and extracted with DCM. The crude intermediate is dissolved in 10 ml DCM and 10 ml 15 TFA and stirred for 1 h at 25 °C. Afterwards the reaction mixture is neutralized with aqueous NaHCO3 solution and extracted with DCM. The organic layer is separated and dried over MgSO4 and the solvent is evaporated. The crude product is purified using reversed phase chromatography (Method: prep. HPLC1).
Yield: 33 % (93 mg; 0.21 mmol)
HPLC-MS: (M+H)+ = 439; tRet = 0.77 min; method VAB
N-[6-(l-benzyl-lH-l,3-benzodiazoI-2-yl)-3-methyl-[l,2,4]triazolo[4,3a]pyrazin-8-yl]-l-methylpiperidin-4-amine
N-[6-(l-benzyl-lH-l,3-benzodiazol-2-yl)-3-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8yl]piperidin-4-amine (93 mg; 0.21 mmol) is dissolved in 300 μΐ THF, treated with
DIPEA (62 μΐ; 0.29 mmol) and formaldéhyde (62 μΐ; 0.83 mmol). To this reaction mixture ST AB (62 mg; 0.29 mmol) is added and the reaction mixture is stirred for 2 hours. The crude reaction mixture is purified by reversed phase chromatograph (Method: prep. HPLC1).
Yield: 60 % (58 mg; 0.13 mmol)
HPLC-MS: (M+H)+ = 453; tRet = 1.19 min; method LCMSBAS1
According to III-1 the following examples are synthesized.
MS (M+H)+; HPLCtRet. HPLC [min] Method
SR*
LCMSBAS1
M+H= 511; tRet = 1.23
LCMSBAS1
MS (M+H)+;
HPLCtRCt. HPLC [min] Method
M+H=511;
tRet = 1.23
M+H= 497; tRet = 1-19
M+H= 515;
tRet.= 1-2
M+H= 533; tRet .= 1-22
LCMSBAS1
LCMSBAS1
LCMSBAS1
LCMSBAS1
Structure
MS (Μ+Η)+; tRet. HPLC [min]
HPLCMethod
ΙΠ-7
ΠΙ-8
ΙΠ-9
ΙΠ-10
ΠΙ-11
M+H= 370;
tRet.= 1-14
M+H= 469; tRet= 1.01
LCMSBAS1
LCMSBAS1
M+H= 454; tRet.= 1-03 | LCMSBAS1 |
M+H=371; tRet = 1.03 | LCMSBAS1 |
M+H= 470; tRet.= 1-08 | LCMSBAS1 |
MS (M+H)+; tRet. HPLC [min] | HPLCMethod |
M+H= 582; | LCMSBAS1 |
ÎRet.= 1-1 |
M+H= 468; tRet.= 1-06 | LCMSBAS1 |
M+H= 455; tRet.= 1-07 | LCMSBAS1 |
M+H= 607; tRet.= 1.04 | LCMSBAS1 |
M+H= 480;
tRet.= 1.01
LCMSBAS1
Structure
MS (Μ+Η)+; tRet. HPLC [min]
HPLCMethod
IH-17
ΙΠ-18
ΙΠ-19
ΗΙ-20
ΙΗ-21
M+H= 483;
tRet = 0.77
M+H= 497; tRet = 0.82
M+H= 512; tRet.= 1-23
M+H= 470; tRet = 0.84
M+H= 469; tRet.= 0-88
VAB
VAB
LCMSBASl
LCMSBASl
LCMSBASl # Structure
MS (M+H) ; HPLCtRet. HPLC [min] Method
III-22
III-23
ΙΠ-24
III-25
À
III-26
M+H=457;
ΐκΛ-0.84
M+H= 456; tRet - 0.88
M+H= 513;
ÎRet = 0.86
M+H= 455; tRet = 0.99
M+H= 484; tRet = 0.99
LCMSBAS1
LCMSBAS1
LCMSBAS1
LCMSBAS1
LCMSBAS1
ΠΙ-27
III-28
ΠΙ-29
ΠΙ-30
ΠΙ-31
Structure
MS (Μ+Η)+; tRet. HPLC [min]
HPLCMethod
M+H= 485; tRet = 0.95
M+H= 503; tRet = 1-02
M+H= 499; tRet.” 1-01
M+H= 499; tRet - 1.01
M+H= 443; tRet= 1.02
LCMSBAS1
LCMSBAS1
LCMSBAS1
LCMSBAS1
LCMSBAS1
Structure
MS (M+H)+; tRet. HPLC [min]
HPLCMethod
III-32
III-33
III-34
III-35
III-36
M+H= 442; tRet .= 1.10
M+H= 399; tRet = 1-06
M+H= 429; tRet = 1-06
M+H= 413; tRet.= 1.13
M+H= 414;
tRet.= 0.92
LCMSBAS1
LCMSBAS1
LCMSBAS1
LCMSBAS1
LCMSBAS1
Structure
MS (Μ+Η)+;
HPLCÎRet. HPLC [min] Method
ΙΠ-37
ΙΠ-38
ΙΙΙ-39
ΙΠ-40
ΙΠ-41
Μ+Η= 400; tRet = 0.87
M+H= 499; tRet = 1-02
M+H= 430; tRet = 0.99
M+H= 442;
tRet.= 1.08
M+H= 513; tRet = 1-09
LCMSBAS1
LCMSBAS1
LCMSBAS1
LCMSBAS1
LCMSBAS1
HI-42
ΠΙ-43
ΙΙΙ-44
ΗΙ-45
ΗΙ-46
Structure
MS (Μ+Η)+; HPLCtRet HPLC [min] Method
LCMSBAS1
LCMSBAS1
LCMSBAS1
M+H= 497;
ÎRet. 1-16
M+H= 455;
tRet.= 1.35
LCMSBAS1
LCMSBAS1
ΙΠ-47
ΙΠ-48
ΙΙΙ-49
ΙΙΙ-50
ΠΙ-51
Structure
MS (M+H)+; ÎRet. HPLC [min] | HPLCMethod |
M+H= 470; tRet .= 0.81 | LCMSBAS1 |
Μ+Η=469;
ÎRet = 0.85
M+H- 457; tRet = 0.81
M+H-456;
ÏRet.= 0.86
M+H-513;
tRet.= 0.82
LCMSBAS1
LCMSBAS1
LCMSBAS1
LCMSBAS1
MS (M+H)+;
HPLCtRet. HPLC [min] Method
LCMSBASl
M+H= 470; tRet = 0.81
LCMSBASl
Biological Methods
BRD4-H4 tetraacetylated peptide inhibition AlphaScreen
This assay is used to détermine whether the compounds inhibit the interaction between the first (BRD4-BD1) or the second (BRD4-BD2) bromodomain of BRD4 and the tetraacetylated histone H4 peptide.
Compounds are diluted in serial dilution 1:5 in assay buffer from lOmM stock in
DMSO (100 μΜ start concentration) in white OptiPlate-384 (PerkinElmer). A mix consisting of 15nM GST-BRD4-BD1 protein (aa 44-168) or 150nM GST-BRD4BD2 (aa 333-460) and 15 nM biotinylated Acetyl-Histone H4 (Lys5, 8, 12, 16) peptide is prepared in assay buffer (50mM HEPES pH=7.4; 25mM NaCl; 0,05% Tween 20; 0.1% bovine sérum albumin (BSA); 10 mM dithiothreitol (DTT)). 6 μΐ of the mix is added to the compound dilutions. Subsequently, 6 μΐ of premixed
AlphaLISA Glutathione Acceptor Beads and AlphaScreen Streptavidin Donor Beads from PerkinElmer (in assay buffer at a concentration of 10 pg/ml each) are added and the samples are incubated for 30 min at RT in the dark (shaking
300 rpm). Afterwards, the signal is measured in a PerkinElmer Envision HTS Multilabel Reader using the AlphaScreen protocol from PerkinElmer.
Each plate contains négative Controls where biotinylated Acetyl-Histone H4 peptide and GST-BRD4-BD1 or GST-BRD4-BD2 are left out and replaced by assay buffer. Négative control values are entered as low basis value when using the software GraphPad Prism for calculations. Furthermore, a positive control (probe molécule JQ1 + with protein/ peptide mix) is pipetted. Détermination of IC50 values are carried out using GraphPad Prism 3.03 software (or updates thereof).
Table summarizing the IC50 of the compounds of the invention exemplified above
Ex# | BRD4-BD1 IC50 [nM] | Ex# | BRD4-BD1 IC50 [nM] | Ex# | BRD4-BD1 IC50 [nM] |
1-1 | 61 | ΙΠ-1 | 7 | ΙΠ-28 | 1 |
1-2 | 41 | III-2 | 41 | ΠΙ-29 | 9 |
1-3 | 41 | III-3 | 49 | III-30 | 9 |
1-4 | 18 | III-4 | 8 | ΠΙ-31 | 13 |
1-5 | 8 | III-5 | 9 | III-32 | 7 |
II-l | 4 | III-6 | 9 | ΠΙ-33 | 20 |
II-2 | 15 | III-7 | 22 | III-34 | 45 |
II-3 | 31 | ΙΠ-8 | 9 | III-35 | 15 |
III-9 | 14 | III-36 | 28 | ||
III-10 | 18 | III-37 | 14 | ||
in-n | 9 | III-38 | 17 | ||
III-12 | 7 | ΙΠ-39 | 126 | ||
III-13 | 9 | III-40 | 18 | ||
m-14 | 10 | III-41 | 74 | ||
III-15 | 3 | III-42 | 66 | ||
III-16 | 5 | III-43 | 34 | ||
ΠΙ-17 | 17 | III-44 | 32 | ||
ΠΙ-18 | 26 | ΙΠ-45 | 69 |
ΠΙ-19 | - 38 | ΠΙ-46 | 243 | ||
III-20 | 13 | III-47 | 12 | ||
III-21 | 8 | ΙΠ-48 | 8 | ||
III-22 | 3 | ΙΠ-49 | 4 | ||
III-23 | 3 | ΙΠ-50 | 5 | ||
III-24 | 20 | ΠΙ-51 | 13 | ||
III-25 | 11 | III-52 | 31 | ||
ΠΙ-26 | 5 | ΠΙ-53 | 12 | ||
ΠΙ-27 | 10 |
On the basis of their biological properties the compounds of general formula (1) according to the invention, their tautomers, racemates, enantiomers, diastereomers, 5 mixtures thereof and the salts of ail the above-mentioned forms are suitable for treating diseases characterised by virus infection, inflammatory diseases and abnormal cell prolifération, such as cancer.
For example, the following cancers may be treated with compounds according to 10 the invention, without being restricted thereto: brain tumours such as for example acoustic neurinoma, astrocytomas such as pilocytic astrocytomas, fibrillary astrocytoma, protoplasmic astrocytoma, gemistocytary astrocytoma, anaplastic astrocytoma and glioblastoma, brain lymphomas, brain métastasés, hypophyseal tumour such as prolactinoma, HGH (human growth hormone) producing tumour 15 and ACTH producing tumour (adrenocorticotropic hormone), craniopharyngiomas, medulloblastomas, meningeomas and oligodendrogliomas; nerve tumours (neoplasms) such as for example tumours of the végétative nervous System such as neuroblastoma sympathicum, ganglioneuroma, paraganglioma (pheochromocytoma, chromaffmoma) and glomus-caroticum tumour, tumours on 20 the peripheral nervous System such as amputation neuroma, neurofibroma, neurinoma (neurilemmoma, Schwannoma) and malignant Schwannoma, as well as tumours of the central nervous system such as brain and bone marrow tumours; intestinal cancer such as for example carcinoma of the rectum, colon carcinoma, colorectal carcinoma, anal carcinoma, carcinoma of the large bowel, tumours of the 25 small intestine and duodénum; eyelid tumours such as basalioma or basal cell carcinoma; pancreatic cancer or carcinoma of the pancréas, bladder cancer or carcinoma of the bladder; lung cancer (bronchial carcinoma) such as for example small-cell bronchial carcinomas (oat cell carcinomas) and non-small cell bronchial carcinomas (NSCLC) such as plate épithélial carcinomas, adenocarcinomas and large-cell bronchial carcinomas; breast cancer such as for example mammary carcinoma such as infiltrating ductal carcinoma, colloid carcinoma, lobular invasive carcinoma, tubular carcinoma, adenocystic carcinoma and papillary carcinoma; non-Hodgkin's lymphomas (NHL) such as for example Burkitt's lymphoma, low-malignancy non-Hodgkin's lymphomas (NHL) and mucosis fungoides; uterine cancer or endométrial carcinoma or corpus carcinoma; CUP syndrome (Cancer of Unknown Primary); ovarian cancer or ovarian carcinoma such as mucinous, endométrial or serous cancer; gall bladder cancer; bile duct cancer such as for example Klatskin tumour; testicular cancer such as for example seminomas and non-seminomas; lymphoma (lymphosarcoma) such as for example malignant lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas (NHL) such as chronic lymphatic leukaemia, leukaemic reticuloendotheliosis, immunocytoma, plasmocytoma (multiple myeloma (MM)), immunoblastoma, Burkitt's lymphoma, T-zone mycosis fungoides, large-cell anaplastic lymphoblastoma and lymphoblastoma; laryngeal cancer such as for example tumours of the vocal cords, supraglottal, glottal and subglottal laryngeal tumours; bone cancer such as for example osteochondroma, chondroma, chondroblastoma, chondromyxoid fibroma, osteoma, osteoid osteoma, osteoblastoma, éosinophilie granuloma, giant cell tumour, chondrosarcoma, osteosarcoma, Ewing's sarcoma, reticulo-sarcoma, plasmocytoma, fibrous dysplasia, juvénile bone cysts and aneurysmatic bone cysts; head and neck tumours such as for example tumours of the lips, tongue, floor of the mouth, oral cavity, gums, palate, salivary glands, throat, nasal cavity, paranasal sinuses, larynx and middle ear; liver cancer such as for example liver cell carcinoma or hepatocellular carcinoma (HCC); leukaemias, such as for example acute leukaemias such as acute lymphatic/lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML); chronic leukaemias such as chronic lymphatic leukaemia (CLL), chronic myeloid leukaemia (CML); stomach cancer or gastric carcinoma such as for example papillary, tubular and mucinous adenocarcinoma, signet ring cell carcinoma, adenosquamous carcinoma, small-cell carcinoma and undifferentiated carcinoma; melanomas such as for example superficially spreading, nodular, lentigo-maligna and acral-lentiginous melanoma; rénal cancer such as for example kidney cell carcinoma or hypemephroma or Grawitz's tumour; oesophageal cancer or carcinoma of the oesophagus; penile cancer; prostate cancer; throat cancer or carcinomas of the pharynx such as for example nasopharynx carcinomas, oropharynx carcinomas and hypopharynx carcinomas; retinoblastoma such as for example vaginal cancer or vaginal carcinoma; plate épithélial carcinomas, adenocarcinomas, in situ carcinomas, malignant melanomas and sarcomas; thyroid carcinomas such as for example papillary, follicular and medullary thyroid carcinoma, as well as anaplastic carcinomas; spinalioma, epidormoid carcinoma and plate épithélial carcinoma of the skin; thymomas, cancer of the urethra and cancer of the vulva.
Preferred cancers, which may be treated with compounds according to the invention, are hematopoietic malignancies (including but not limited to AML, MM), as well as solid tumors including but not limited to lung, liver, colon, brain, thyroid, pancréas, breast, ovary and prostate cancer.
The new compounds may be used for the prévention, short-term or long-term treatment of the above-mentioned diseases, optionally also in combination with radiotherapy or other state-of-the-art compounds, such as e.g. cytostatic or cytotoxic substances, cell prolifération inhibitors, anti-angiogenic substances, steroids or antibodies.
The compounds of general formula (I) may be used on their own or in combination with other active substances according to the invention, optionally also in combination with other pharmacologically active substances.
Chemotherapeutic agents which may be administered in combination with the compounds according to the invention, include, without being restricted thereto, hormones, hormone analogues and antihormones (e.g. tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, flutamide, nilutamide, bicalutamide, aminoglutéthimide, cyproterone acetate, fmasteride, buserelin acetate, fludrocortisone, fluoxymesterone, medroxyprogesterone, octreotide), aromatase inhibitors (e.g. anastrozole, letrozole, liarozole, vorozole, exemestane, atamestane), LHRH agonists and antagonists (e.g. goserelin acetate, luprolide), inhibitors of growth factors (growth factors such as for example platelet derived growth factor and hépatocyte growth factor, inhibitors are for example growth factor antibodies, growth factor receptor antibodies and tyrosine kinase inhibitors, such as for example cetuximab, gefitinib, imatinib, lapatinib and trastuzumab); antimetabolites (e.g. antifolates such as methotrexate, raltitrexed, pyrimidine analogues such as 5-fluorouracil, capecitabin and gemcitabin, purine and adenosine analogues such as mercaptopurine, thioguanine, cladribine and pentostatin, cytarabine, fludarabine); antitumour antibiotics (e.g. anthracyclins such as doxorubicin, daunorubicin, epirubicin and idarubicin, mitomycin-C, bleomycin, dactinomycin, plicamycin, streptozocin); platinum dérivatives (e.g. cisplatin, oxaliplatin, carboplatin); alkylation agents (e.g. estramustin, meclorethamine, melphalan, chlorambucil, busulphan, dacarbazin, cyclophosphamide, ifosfamide, temozolomide, nitrosoureas such as for example carmustin and lomustin, thiotepa); antimitotic agents (e.g. Vinca alkaloids such as for example vinblastine, vindesin, vinorelbin and vincristine; and taxanes such as paclitaxel, docetaxel); topoisomerase inhibitors (e.g. epipodophyllotoxins such as for example etoposide and etopophos, teniposide, amsacrin, topotecan, irinotecan, mitoxantron) and varions chemotherapeutic agents such as amifostin, anagrelid, clodronat, filgrastin, interferon alpha, leucovorin, rituximab, procarbazine, levamisole, mesna, mitotane, pamidronate and porfimer.
Other possible combination partners are 2-chlorodesoxyadenosine, 2-fluorodesoxycytidine, 2-methoxyoestradiol, 2C4, 3-alethine, 131-I-TM-601, 3CPA, 7-ethyl-10-hydroxycamptothecin, 16-aza-epothilone B, A 105972, A 204197, aldesleukin, alitretinoin, altretamine, alvocidib, amonafide, anthrapyrazole, AG-2037, AP-5280, apaziquone, apomine, aranose, arglabin, arzoxifene, atamestane, atrasentan, auristatin PE, AVLB, AZ10992, ABX-EGF, ARRY-300, ARRY-142886/AZD-6244, ARRY-704/AZD-8330, AS-703026, azacytidine, azaepothilone B, azonafide, BAY-43-9006, BBR-3464, BBR-3576, bevacizumab, biricodar dicitrate, BCX-1777, bleocin, BLP-25, BMS-184476, BMS-247550, BMS-188797, BMS-275291, BNP-1350, BNP-7787, BIBW 2992(afatinib), BIBF 1120 (Vargatef™), bleomycinic acid, bleomycin A, bleomycin B, bryostatin-1, bortezomib, brostallicin, busulphan, CA-4 prodrug, CA-4, CapCell, calcitriol, canertinib, canfosfamide, capecitabine, carboxyphthalatoplatin, CCI-779, CEP-701, CEP-751, CBT-1 cefixime, ceflatonin, ceftriaxone, celecoxib, celmoleukin, cemadotin, CH4987655/RO-4987655, chlorotrianisene, cilengitide, ciclosporin, CDA-II, CDC-394, CKD-602, clofarabin, colchicin, combretastatin A4, CHS-828, CLL-Thera, CMT-3 cryptophycin 52, CTP-37, CP-461, CV-247, cyanomorpholinodoxorubicin, cytarabine, D 24851, decitabine, deoxorubicin, deoxyrubicin, deoxycoformycin, depsipeptide, desoxyepothilone B, dexamethasone, dexrazoxanet, diethylstilbestrol, diflomotecan, didox, DMDC, dolastatin 10, doranidazole, E7010, E-6201, edatrexat, edotreotide, efaproxiral, eflomithine, EKB-569, EKB-509, elsamitrucin, epothilone B, epratuzumab, ER-86526, erlotinib, ET-18-OCH3, ethynylcytidine, ethynyloestradiol, exatecan, exatecan mesylate, exemestane, exisulind, fenretinide, floxuridine, folie acid, FOLFOX, FOLFIRI, formestane, galarubicin, gallium maltolate, gefinitib, gemtuzumab, gimatecan, glufosfamide, GCS-IOO, G17DT immunogen, GMK, GPX-100, GSK-5126766, GSK-1120212, GW2016, granisetron, hexamethylmelamine, histamine, homoharringtonine, hyaluronic acid, hydroxyurea, hydroxyprogesterone caproate, ibandronate, ibritumomab, idatrexate, idenestrol, IDN-5109, IMC-1C11, immunol, indisulam, interferon alpha-2a, interferon alfa-2b, interleukin-2, ionafamib, iproplatin, irofiilven, isohomohalichondrin-B, isoflavone, isotretinoin, ixabepilone, JRX-2, JSF-154, J-107088, conjugated oestrogens, kahalid F, kétoconazole, KW-2170, lobaplatin, leflunomide, lenograstim, leuprolide, leuporelin, lexidronam, LGD-1550, linezolid, lutetium texaphyrin, lometrexol, losoxaritrone, LU 223651, lurtotecan, mafosfamide, marimastat, mechloroethamine, methyltestosteron, méthylprednisolone, MEN-10755, MDX-H210, MDX-447, MGV, midostaurin, minodronic acid, mitomycin, mivobulin, MK-2206, MLN518, motexafin gadolinium, MS-209, MS-275, MX6, neridronate, neovastat, nimesulide, nitroglycerin, nolatrexed, norelin, N-acetylcysteine, 06-benzylguanine, omeprazole, oncophage, ormiplatin, ortataxel, oxantrazole, oestrogen, patupilone, pegfilgrastim, PCK-3145, pegfilgrastim, PBI-1402, PEG-paclitaxel, PEP-005, P-04, PKC412, P54, PI-88, pelitinib, pemetrexed, pentrix, perifosine, perillylalcohol, PG-TXL, PG2, PLX-4032/RO-5185426, PT-100, picoplatin, pivaloyloxymethylbutyrate, pixantrone, phenoxodiol O, PKI 166, plevitrexed, plicamycin, polyprenic acid, porfïromycin, prednisone, prednisolone, quinamed, quinupristin, RAF-265, ramosetron, ranpimase, RDEA-119/BAY 869766, rebeccamycin analogues, revimid, RG-7167, rhizoxin, rhu-MAb, risedronate, rituximab, rofecoxib, Ro-317453, RO-5126766, RPR 109881A, rubidazon, rubitecan, R-flurbiprofen, S-9788, sabarubicin, SAHA, sargramostim, satraplatin, SB 408075, SU5416, SU6668, SDX-101, semustin, seocalcitol, SM-11355, SN-38, SN-4071, SR-27897, SR-31747, SRL-172, sorafenib, spiroplatin, squalamine, suberanilohydroxamic acid, sutent, T 900607, T 138067, TAS-103, tacedinaline, talaporfin, tariquitar, taxotere, taxoprexin, tazarotene, tegafur, temozolamide, tesmilifene, testosterone, testosterone propionate, tesmilifene, tetraplatin, tetrodotoxin, tezacitabine, thalidomide, theralux, therarubicin, thymectacin, tiazofurin, tipifarnib, tirapazamine, tocladesine, tomudex, toremofin, trabectedin, TransMID-107, transretinic acid, traszutumab, tretinoin, triacetyluridine, triapine, trimetrexate, TLK-286TXD 258, urocidin, valrubicin, vatalanib, vincristine, vinflunine, virolizin, WX-UK1, vectibix, Volasertib (or other polo-like kinae inhibitors), xeloda, XELOX, XL-281, XL-518/R-7420, YM-511, YM-598, ZD-4190, ZD-6474, ZD-4054, ZD-0473, ZD-6126, ZD-9331, ZDI839, zoledronat and zosuquidar.
Suitable préparations include for example tablets, capsules, suppositories, solutions - particularly solutions for injection (s.c., i.v., i.m.) and infusion - élixirs, émulsions or dispcrsible powders. The content of the pharmaceutically active compound(s) should be in the range from 0.1 to 90 wt.-%, preferably 0.5 to 50 wt.-% of the composition as a whole, i.e. in amounts which are sufficient to achieve the dosage range specified below. The doses specified may, if necessary, be given several times a day.
Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as com starch or alginic acid, binders such as starch or gélatine, lubricants such as magnésium stéarate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
Syrups or élixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
Solutions for injection and infusion are prepared in the usual way, e.g. with the addition of isotonie agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali métal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, whilst if water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aids, and transferred into injection vials or ampoules or infusion bottles.
Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gélatine capsules.
Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the dérivatives thereof.
Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffine (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. éthanol or glycerol), carriers such as e.g. natural minerai powders (e.g. kaolins, clays, talc, chalk), synthetic minerai powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose) emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnésium stéarate, talc, stearic acid and sodium lauryl sulphate).
The préparations are administered by the usual methods, preferably by oral or transdermal route, most preferably by oral route. For oral administration the tablets may, of course contain, apart from the abovementioned carriers, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gélatine and the like. Moreover, lubricants such as magnésium stéarate, sodium lauryl sulphate and talc may be used at the same time for the tabletting process. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above.
For parentéral use, solutions of the active substances with suitable liquid carriers may be used.
However, it may sometimes be necessary to départ from the amounts specified, depending on the body weight, the route of administration, the individual response to the drug, the nature of its formulation and the time or interval over which the drug is administered. Thus, in some cases it may be sufficient to use less than the minimum dose given above, whereas in other cases the upper limit may hâve to be exceeded. When administering large amounts it may be advisable to divide them up into a number of smaller doses spread over the day.
The formulation examples which follow illustrate the présent invention without restricting its scope:
Examples of pharmaceutical formulations
A) Tablets___ | _______per tablet |
active substance according to formula (I) lactose | 100 mg 140 mg |
corn starch polyvinylpyrrolidone magnésium stéarate | 240 mg 15 mg 5 mg 500 mg |
The fmely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnésium stéarate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.
B) Tablets_________________________________________ | _______per tablet |
active substance according to formula (I) lactose | 80 mg 55 mg |
corn starch microcrystalline cellulose polyvinylpyrrolidone sodium-carboxymethyl starch magnésium stéarate | 190 mg 35 mg 15 mg 23 mg 2mg |
400 mg
The fïnely ground active substance, some of the com starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining com starch and water to form a granulate which is dried and screened. The sodiumcarboxymethyl starch and the magnésium stéarate are added and mixed in and the mixture is compressed to form tablets of a suitable size.
C) Ampoule solution active substance according to formula (I) sodium chloride water for inj.
mg mg mL
The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonie. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptie conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.
Claims (22)
1. A compound of formula (I)
(I) wherein,
R1 is -Ci.3alkyl or -Ci.3haloalkyl;
R2 is selected from -NHR4, -Ci-salkyl, -Ci.5haloalkyl, halogen and -S-Ci.3alkyl;
R is a 5-12 membered heteroaryl, which group is substituted with -X-R and optionally further substituted with one or more groups independently selected from R9;
R4 is selected from -Ci-salkyl and 5-12 memebered heterocycloalkyl, which heterocycloalkyl can be optionally substituted with one or more groups independently selected from R5;
R5 is selected from -Cj.5alkyl, -Ci.5haloalkyl and -Ci.3alkylene-O-Ci.3alkyl;
R9is selected from -Ci.5alkyl, -O-Ci.5alkyl, -N(Ci.5alkyl)2, halogen, -Ci.3alkylene-O-Ci.3alkyl, -Ci.5alkylene-N(-Ci-5alkyl, -Ci.5alkyl), 5-12 memebered heterocycloalkyl,wherein the heterocycloalkyl group can be optionally substituted with one or more groups independently selected from =O, -Ci.3alkyl, or
R9 is selected from -Cô-ioaryl and 5-12 memebered heteroaryl, wherein the aryl and heteroaryl groups can be optionally and independently substituted with one ore more groups selected from halogen, -Ci.3alkyl, -O-Cisalkyl, -C].3haloalkyl, -O-Ci.3haloalkyl, -N(Ci-5alkyl, Ci-salkyl) and -NH-C^alkyl;
X is -Ci-3alkylene- or -O-;
R10 is-Cô-ioaryl or 5-12 membered heteroaryl, each of which groups can be optionally substituted with one or more groups selected from halogen, -Ci^alkyl, -O-Ci-3alkyl, -Ci^haloalkyl, -O-Ci.3haloalkyl;
wherein the compounds of formula (I) may be optionally be présent in the form of salts.
2. A compound according to claim 1, wherein R1 is -CH3.
3. A compound according to claim 1 or 2, wherein R2 is -NHR4 5 6 7 8 * and R4 is a 5-6 membered heterocycloalkyl, optionally substituted as defined in claim 1.
4. A compound according to claim 3, wherein R4 is tetrahydrofuran or piperidine, wherein the piperidine is substituted with one group selected from -CH3, -CH2CH3,-CH2CH2CH3 and -(CH2)2-O-CH3.
5. A compound according to anyone of claims 1 or 2, wherein R2 is -NHR4 and R4 is -Ci-3alkyl.
6. A compound according to claim 5, wherein R2 is -NHR4 and R4 is -CH3 or -CH(CH3)2.
7. A compound according to anyone of claims 1 or 2, wherein R2 is -Ci-3alkyl.
8. A compound according to anyone of claims 1 to 7, wherein R is a 5-9 membered heteroaryl substituted with -X-R10 and optionally further substituted with one or more groups independently selected from R9, wherein R9, X and R10 are defined as in claim 1.
9. A compound according to anyone of daims 1 to 8, wherein -X-R10 is selected from -CH2-phenyl, -CH(CH3)-phenyl, -CH2-pyridyl, -CH(CH3)-pyridyl, -O-phenyl, each of which phenyl or pyridyl groups is optionally substituted with -F or -CH3.
10. A compound according to claim 9, wherein -X-R10 is selected from -CH2phenyl, -CH2-pyridyl, -CH(CH3)-phenyl, -CH(CH3)-pyridyl, each of which pyridyl or phenyl group is optionally substituted with —F or —CH3.
11. A compound according to claim 8, wherein R3 is selected from pyrazolyl, imidazol, benzimidazolyl, imidazopyridine and imidazopyrimidine and R is substituted with -X-R10 and R3 is optionally further substituted with one or more groups independently selected from R9 wherein R9, X and R10 are defined as in claim 1.
12. A compound according to anyone of claims 1 to 11, wherein R9 is independently selected from -Ci.3alkyl, -O-Ci_3alkyl, -N(Ci-3alkyl)2, phenyl and 6 membered heterocycloalkyl, which heterocycloalklyl can be optionally substituted with one or more groups independently selected =O and -Ci^alkyl.
13. A compound according to claim 11, wherein R3 is imidazopyridine or benzimidazol substituted with -CH2-phenyl or -CH2-pyridyl, -CH(CH3)pyridyl and optionally further substituted with -C|.3alkyl or 5-12 memebered heterocycloalkyl wherein the heterocycloalkyl group can be optionally substituted with one or more groups independently selected from -Ci-3alkyl.
14. A compound according to claim 13, wherein R3 is imidazopyridine or benzimidazol substituted with -CH2-phenyl, -CH(CH3)-pyridyl or -CH2pyridyl and with -CH(CH3 )2 or morpholinyl or piperazinyl, wherein the morpholinyl or piperazinyl groups is optionally substituted with one or more groups selected from -Ci-3alkyl.
15. A compound according to claim 1 selected from
EX# Structure Ex # Structure
EX#
Structure
III-ll
\=N
An
vd
/
III-13
\=N
ΓγΝ ^/N;y^rr''NH / \—-N ।
/
ΙΠ-15
\=N
An
H-n
A
ΠΙ-17
\=N n?n
ΝγΑΑΗ y}y
O O
/
III-19
Z
Ex#
Structure
III-12
\:=N zNY^N^NH
°\
ΠΙ-14
\=N nAn /nY^n^nh À
ΠΙ-16
\=N N^'N
N-N DV^AnH
0 AyA
III-18
\=N\ nAN ^/N;Y^n^nh y# N\
OO /
III-20
EX#
Structure
ΙΠ-31
:
1
ΙΠ-33
'y=N , *ΧΧ φ -
ΠΙ-35
\=Ν ν^ν
φ A
ΙΠ-37
\=Ν
Μ >>Ν ^/Ν^γ^Ν^ΝΗ dA A w
ΠΙ-39
À vW
Ex#
Structure
ΠΙ-32
\=N
it
Λ
W
ΠΙ-34
uX.
-φ A w
III-36
\=N N-^N /N<Af n^nh Φ A w
III-38
\=N
it
_/^γ^Ν^ΝΗ
y>X a<
OQ
ΙΠ-40
\=N it i'i o
wherein the compound may be optionally be présent in the form of salts.
16. A compound of general formula (I) according to anyone of daims 1 to 15 - or the pharmaceutically acceptable salts thereof - for use in the treatment and/or 5 prévention of cancer.
17. Pharmaceutical préparation comprising as active substance one or more compounds of general formula (I) according to anyone of daims 1 to 15 optionally in combination with conventional excipients and/or carriers.
18. Pharmaceutical préparation comprising a compound of general formula (I) 10 according to anyone of daims 1 to 15 - or one of the pharmaceutically acceptable salts thereof - and at least one other cytostatic or cytotoxic active substance, different from formula (I).
19. A compound of general formula (I) according to anyone of daims 1 to 15 or the pharmaceutically acceptable salts thereof - for use as médicaments.
20. A compound of general formula (I) according to anyone of claims 1 to 15 - or the pharmaceutically acceptable salts thereof - for use in the treatment of hematopoietic malignancies.
21. A compound of general formula (I) according to anyone of claims 1 to 15
5 - or the pharmaceutically acceptable salts thereof - for use in the treatment of
AML or MM.
22. A compound of general formula (I) according to anyone of claims 1 to 15 - or the pharmaceutically acceptable salts thereof - for use in the treatment of lung, liver, colon, brain, thyroid, pancréas, breast, ovary and prostate cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12192987.1 | 2012-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA19258A true OA19258A (en) | 2020-06-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11077107B2 (en) | Triazolopyrazine | |
EP2978757B1 (en) | Indolinone analogues as brd4 inhibitors | |
EP3066104B1 (en) | Triazolopyrazine derivatives as brd4 inhibitors | |
EP2978758B1 (en) | Dihydroquinazolinone analogues as brd4 inhibitors | |
EP3033335B1 (en) | Pyridinones | |
EP2920175B1 (en) | Triazolopyridazine derivatives as bromodomain inhibitors | |
EP3140304B1 (en) | Benzimidazole derivatives | |
WO2015025018A1 (en) | New bis-amido pyridines | |
EP2571877A1 (en) | 1h - imidazo [4, 5 - c]quinolines | |
EP2668178B1 (en) | New 5-alkynyl-pyridines | |
OA19258A (en) | Triazolopyrazine |